Peptide receptor radionuclide therapy
Patent Information
- Application Number
- JP2023533889
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-04
- Filing Date
- 2021-12-03
- Publication Date
- 2024-12-05
AI Technical Summary
Current treatments for cancers such as pancreatic ductal adenocarcinoma (PDAC) are ineffective, with gemcitabine being the only chemotherapy showing a less than 10% clinical response and providing an average survival benefit of only 6 weeks, highlighting a significant unmet need for new and more effective therapies.
Administration of a therapeutic conjugate comprising a PEGylated peptide with the sequence GNGVPNLRGDLQVLGQRVGRT, conjugated with a radionuclide like 177Lu, specifically targeting αvβ6 integrins overexpressed in various cancers, including PDAC, to deliver targeted radiation therapy.
The therapy results in stable disease, partial remission, or complete remission, reduces tumor volume and metastasis, and increases the responsiveness of cancer to subsequent anti-cancer agents, offering a more effective treatment option for integrin-related cancers.
Smart Images

Figure 00000000_0000_ABST
Abstract
Description
[Technical Field]
[0001] Cross-reference of related applications This application claims the benefit of U.S. Provisional Patent Application No. 63 / 121,762, filed on December 4, 2020, and by reference thereto, the entire disclosure thereof is incorporated herein by reference. [Background technology]
[0002] background Cancer continues to demand new and more effective treatments. In particular, some cancers and subsets of those types of cancer are refractory to current approaches. For example, the incidence of pancreatic ductal adenocarcinoma (PDAC) continues to rise, with an estimated 47,000 people diagnosed with pancreatic adenocarcinoma in the United States in 2018. Unfortunately, PDAC remains the deadliest cancer, with 98% of those ultimately dying from it. Despite thorough examination and advancements in first- and second-line treatments, only one chemotherapy regimen (gemcitabine) has proven effective against this disease. However, the clinical response rate remains below 10%, extending life by an average of only six weeks. Coupled with the lack of clinical options for pancreatic cancer, these unfavorable results highlight a clearly unmet need for research into new treatments. [Overview of the Initiative]
[0003] overview In one aspect, this disclosure is α v A method for treating β6 integrin-related cancers is provided, comprising administering a certain dose of a therapeutic conjugate of formula I to a subject in need of treatment. In the TIFF2023552383000002.tif61128 formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. and A certain dose of therapeutic conjugate contains approximately 25 mCi to 200 mCi of radioactivity.
[0004] In related aspects, this disclosure is α v We provide a therapeutic conjugate for use in a method for treating β6 integrin-related cancers, the method comprising administering a certain dose of the therapeutic conjugate to a subject in need of treatment, the therapeutic conjugate comprising formula I, In the TIFF2023552383000003.tif62128 formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. and A certain dose of therapeutic conjugate contains approximately 25 mCi to 200 mCi of radioactivity.
[0005] In some embodiments, the first PEG portion and the second PEG portion are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In some embodiments, the first PEG portion and the second PEG portion are the same. In certain embodiments, the first PEG portion and the second PEG portion each include PEG28 (PEG1500).
[0006] In some embodiments, the amount of radioactivity in the dose is 25 mCi, 50 mCi, 100 mCi, 150 mCi, or 200 mCi. In some embodiments, the method further includes administering one, two, or three additional doses of the therapeutic conjugate to the subject. In some embodiments, the doses include about 500 μg, about 400 μg, about 300 μg, about 200 μg, or less than about 100 μg of peptide. In certain embodiments, the doses include about 100 μg or less of peptide. In embodiments in which multiple doses of the therapeutic conjugate are administered to the subject, each dose may contain the same or different doses of radioactivity and / or the same or different amounts of peptide.
[0007] In some embodiments, α v β6 integrin-related cancers include pancreatic cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, cutaneous squamous cell carcinoma, gastric cancer, or endometrial cancer. In certain embodiments, pancreatic cancer is locally advanced or metastatic pancreatic cancer; locally advanced, unresectable, or metastatic pancreatic adenocarcinoma; or ductal adenocarcinoma (PDAC).
[0008] In some embodiments, α v β6 integrin-related cancers include primary lesions and metastatic lesions. In certain embodiments, α v β6 integrin-related cancers include lesions in the adrenal glands, bones, brain, liver, lungs, or any combination thereof.
[0009] In some embodiments, the subject receives standard treatment before a certain dose of the therapeutic conjugate is administered. In some embodiments, the subject receives standard treatment after a certain dose of the therapeutic conjugate is administered. In some embodiments, the subject receives standard treatment both before and after a certain dose of the therapeutic conjugate is administered. In some embodiments, standard treatment includes one or more of surgery, radiotherapy, chemotherapy, chemoradiotherapy, and targeted therapy. In certain embodiments, standard treatment includes FOLFIRINOX (leucovorin calcium (folic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin), gemcitabine, Abraxane, irinotecan, or a combination thereof.
[0010] In some embodiments, the method further includes scanning the subject's body or a part thereof after administration of a therapeutic conjugate. In certain embodiments, the scanning includes positron emission tomography (PET), computed tomography (CT) scanning, or single-photon emission computed tomography (SPECT).
[0011] In some embodiments, the method further comprises administering a diagnostic conjugate before administering a therapeutic conjugate, the diagnostic conjugate comprising the RGD peptide and a second radionuclide, such as a different radionuclide suitable for imaging. In certain embodiments, the second radionuclide is 68 It is Ga. In certain embodiments, the diagnostic conjugate is administered in a dose containing up to about 5 mCi of radioactivity (e.g., greater than about 0.01 mCi to about 5 mCi).
[0012] In some embodiments, the method further includes scanning the subject's body or a part thereof after administration of a diagnostic conjugate. In certain embodiments, the scanning includes positron emission tomography (PET), computed tomography (CT) scanning, or single-photon emission computed tomography (SPECT).
[0013] In some embodiments, the therapeutic conjugate is administered within 5 weeks after the administration of the diagnostic conjugate.
[0014] In certain embodiments, the diagnostic conjugate includes formula II, In the TIFF2023552383000004.tif51128 formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. That is the case.
[0015] In some embodiments, the first and second PEG portions in the diagnostic conjugate are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In some embodiments, the first and second PEG portions are the same. In certain embodiments, the first and second PEG portions each include PEG28 (PEG1500).
[0016] In some embodiments, the method further includes administering an amino acid solution to the subject. In certain embodiments, the solution is administered before and concurrently with the administration of the therapeutic conjugate.
[0017] In some embodiments, the therapeutic conjugate is administered to the subject by infusion. In some embodiments, the diagnostic conjugate is administered to the subject by injection. In some embodiments, the diagnostic conjugate is administered by bolus, slow bolus, or slow infusion. In some embodiments, the therapeutic conjugate is administered by bolus, slow bolus, or slow infusion. In some embodiments, the diagnostic conjugate is administered by bolus, and the therapeutic conjugate is administered by slow bolus or slow infusion. In some embodiments, the therapeutic conjugate is infused over several minutes or hours, for example, about 1 minute, about 2 minutes, about 5 minutes, about 10 minutes, about 15 minutes, about 20 minutes, about 25 minutes, about 30 minutes, about 35 minutes, about 40 minutes, about 45 minutes, about 55 minutes, about 1 hour, about 2 hours, about 3 hours, about 4 hours, about 5 hours, about 6 hours, about 7 hours, or about 8 hours. In certain embodiments, the therapeutic conjugate is infused over about 30 minutes. In some embodiments, the diagnostic conjugate is injected over a period of several minutes, for example, about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes or less. In certain embodiments, the diagnostic conjugate is injected over a period of about 5 minutes or less.
[0018] In some embodiments, the treatment results in stable disease, partial remission, or complete remission. In some embodiments, the treatment results in a reduction of cancer metastasis in the subject. In some embodiments, the treatment reduces the volume, size, or growth of tumors in the subject. In some embodiments, the treatment increases the cancer's response to subsequently administered anticancer drugs.
[0019] In some embodiments, the amount of therapeutic conjugate present in kidney tissue 24, 48, or 72 hours after administration of the conjugate is less than the amount of therapeutic conjugate present in kidney tissue 1 hour after administration of the conjugate. In some embodiments, the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in kidney tissue 24, 48, or 72 hours after administration of the conjugate is higher than the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in kidney tissue 1 hour after administration of the conjugate.
[0020] In another embodiment, the disclosure provides a pharmaceutical composition comprising a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT.
[0021] In some embodiments, the PEG moiety is covalently bonded to the N-terminus, C-terminus, or both the N-terminus and C-terminus of the peptide. In some embodiments, the PEG moiety is independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In other embodiments, the first PEG moiety is covalently bonded to the N-terminus of the peptide, and the second PEG moiety is covalently bonded to the C-terminus of the peptide, and the first and second PEG moieties are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In some embodiments, the first and second PEG moieties are the same. In certain embodiments, the first and second PEG moieties each contain PEG28 (PEG1500). In some embodiments, the PEG moiety covalently bonded to the C-terminus of the peptide is terminated with an amide, carboxyl group, or hydroxyl group.
[0022] In some embodiments, the peptide is covalently bound to an albumin binding moiety (ABM). In certain embodiments, the ABM comprises 4-(4-iodophenyl)butyric acid. In some embodiments, the ABM comprises a linker such as a peptide linker covalently bound to the peptide, a first PEG moiety, or a second PEG moiety. In certain embodiments, the ABM comprises a K(D-Abu-iodophenylbutyryl) moiety.
[0023] In some embodiments, the peptide is covalently bound to a chelate moiety. In certain embodiments, the chelate moiety is DOTA. In a particular example, the radionuclide complexes with the chelate moiety. In some embodiments, the radionuclide is covalently bound directly or indirectly to the peptide. In some cases, the radionuclide is 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 selected from the group consisting of Bi. In other cases, the radionuclide is 11 C, 13 N, 15 O, 18 F, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 In, 124 I, 125 I, or 131 selected from the group consisting of I. In other cases, the radionuclide is 177 Lu or68 It is Ga.
[0024] In related embodiments, the present disclosure provides a pharmaceutical composition comprising a conjugate of formula I: TIFF2023552383000005.tif61128(In the formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. (is), and Pharmacologically acceptable excipients Includes.
[0025] In some embodiments, the first PEG portion and the second PEG portion are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In some embodiments, the first PEG portion and the second PEG portion are the same. In certain embodiments, the first PEG portion and the second PEG portion each include PEG28 (PEG1500).
[0026] In some embodiments, the composition contains radioactivity ranging from about 25 mCi to about 200 mCi. In specific embodiments, the composition contains radioactivity ranging from 25 mCi, 50 mCi, 100 mCi, 150 mCi, or 200 mCi.
[0027] In other related embodiments, the Disclosure provides a pharmaceutical composition and a conjugate of Formula II: TIFF2023552383000006.tif51128(In the formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. (is), and Pharmacologically acceptable excipients Includes.
[0028] In some embodiments, the first PEG portion and the second PEG portion are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2). In some embodiments, the first PEG portion and the second PEG portion are the same. In certain embodiments, the first PEG portion and the second PEG portion each include PEG28 (PEG1500).
[0029] In some embodiments, the composition contains a maximum of about 5 mCi (e.g., greater than about 0.01 mCi to about 5 mCi) of radioactivity. [Brief explanation of the drawing]
[0030] [Figure 1] Figures 1A and 1B show ELISA binding curves of peptide 1 (DOTA-5G) (Figure 1A) and peptide 2 (DOTA-ABM-5G) (Figure 1B) to integrin αvβ6 in relation to biotinylated LAP (n=3 / integrin / concentration; bar: SD). Figure 1C shows cell binding and internal migration of 68Ga-1 and 177Lu-2 at 37°C using integrin αvβ6(+) BxPC-3 cells. The internal migration fraction is the fraction of total bound radioactivity (n=3 / cell line; 1 hour); bar: SD. Figure 1D shows the percentage of retained radioactivity to determine the efflux of 177Lu-2 from BxPC-3 cells at 37°C. [Figure 2] Representative axial transverse (top) and coronal (bottom) PET / CT sections of mice with BxPC-3 tumors (arrows), obtained 2 hours after injection of 68Ga-1 or 68Ga-2. K=kidney, B=bladder, H=heart. Upper bar of PET scale and lower bar of CT scale below the image. [Figure 3] Figures 3A-D show the in vivo distribution of 68Ga-1 and 68Ga-2 (Figures 3A and 3B, respectively), and 177Lu-1 and 177Lu-2 (Figures 3C and 3D, respectively) in selected organs as attenuation-corrected injection doses per gram of tissue in mice with αvβ6(+)BxPC-3 tumors (n=3 / group / time point), expressed as percentages. [Figure 4] Figures 4A-D show the uptake of 177Lu-1 and 177Lu-2 in (Figure 4A) BxPC-3 tumors, (Figure 4B) kidneys, (Figure 4C) BxPC-3 / kidney ratio, and (Figure 4D) BxPC-3 / stomach ratio. Uptake values are expressed as the percentage of attenuation-corrected injection volume per gram of tissue (%ID / g) in mice with αvβ6(+)BxPC-3 tumors (n=3 / group / time point), derived from in vivo distribution data. [Figure 5] The in vivo distribution of 68Ga-1, determined by radioactivity assay in mice with BxPC-3(αvβ6(+)) tumors, is shown 1 hour after injection (n=3 / group). For block, 1 dose of 8.3 μmol / kg (30 mg / kg) was administered 10 minutes prior to 68Ga-1 administration (n=2 / group). Uptake data are expressed as attenuation-corrected percentage of injected volume per gram of tissue (column: uptake [%ID / g]; bar: SD). [Figure 6] The in vivo distribution of 177Lu-1, determined by radioactivity assay in mice with BxPC-3(αvβ6(+)) tumors, is shown 1 hour after injection (n=3 / group). For block, 1 dose of 8.3 μmol / kg (30 mg / kg) was administered 10 minutes prior to 177Lu-1 administration (n=2 / group). Uptake data are expressed as attenuation-corrected percentage of injected volume per gram of tissue (column: uptake [%ID / g]; bar: SD). [Figure 7] The in vivo distribution of 177Lu-2, determined by radioactivity assay in mice with BxPC-3(αvβ6(+)) tumors 4 hours post-injection, is shown (n=3 / group). For block, 8.3 μmol / kg (48 mg / kg) was administered 10 minutes prior to 177Lu-2 administration (n=1 / group). Uptake data are expressed as attenuation-corrected percentage of injected volume per gram of tissue (column: uptake [%ID / g]; bar: SD). [Figure 8]Figures 8A and 8B show the therapeutic effects of 177Lu-2 in mice with αvβ6(+)BxPC-3 tumors, as determined by tumor volume measurement (Figure 8A) and survival data (Figure 8B). Group 1 = saline control (n=5), Group 2 = peptide 2 control (n=5), Group 3 = 74 MBq 177Lu-2 (n=10), and Group 4 = 2*37 MBq 177Lu-2 (n=7). Mice received their first treatment on day 14 (Group 3) and day 21 (Group 4) after tumor transplantation and were monitored for up to 120 days post-treatment. [Figure 9] Figures 9A and 9B show the body weight of mice measured twice a week until the end of the study (120 days) for treatment group 3 (Figure 9A; 74MBq177Lu-2) and treatment group 4 (Figure 9B; 2*37MBq177Lu-2). [Figure 10] This document shows peptide 1, which was used to construct formula II containing peptide 1 having the 68Ga radionuclide (also referred herein as [68Ga]GaDOTA-5G and 68Ga-1), and peptide 2, which was used to construct formula I containing peptide 2 having the 177Lu radionuclide (also referred herein as [177Lu]LuDOTA-ABM-5G and 177Lu-2). Peptide 1 was also used to construct 177Lu-1, which contains peptide 1 having the 177Lu radionuclide. Peptide 2 was also used to construct 68Ga-2, which contains peptide 2 having the 68Ga radionuclide. [Modes for carrying out the invention]
[0031] Detailed explanation I. Introduction This specification describes the use of peptide receptor radionuclide therapy (PRRT) for integrin subtype α v Methods and related compositions incorporating β6-mediated molecular targeting and theranostic approaches are provided.
[0032] Integrin subtype α vβ6 is an epithelial-specific cell surface receptor that is undetectable in healthy adult epithelium but is significantly upregulated in a wide range of epithelial-derived cancers, including pancreatic ductal adenocarcinoma (PDAC). v β6 was first identified in PDAC and is present in almost all tumors. v Highly upregulated expression of β6 is shown.
[0033] PRRT is a therapy that uses cell-targeting peptides combined with radionuclides. When the radioactive peptides are injected into the patient's bloodstream, they directly deliver a targeted high dose of radiation to cancer cells.
[0034] II. Definition Unless otherwise specifically defined, all technical and scientific terms used herein have the same meaning as those generally understood by those skilled in the art in which the invention pertains. Furthermore, in carrying out this disclosure, any methods and materials similar to or equivalent to those described herein may be used. For the purposes of this disclosure, the following terms are defined:
[0035] As used herein, the terms "a," "an," or "the" include not only aspects involving one member but also aspects involving two or more members. For example, unless explicitly stated otherwise in the context, the singular forms "a," "an," and "the" include multiple referents. Thus, for example, a reference to "conjugate" includes multiple such conjugates.
[0036] The term “approximately” is used herein to modify a number and indicate a defined range around that value. Where “X” is a value, “approximately X” generally refers to values between 0.90X and 1.10X. A reference to “approximately X” refers to at least the values X, 0.90X, 0.91X, 0.92X, 0.93X, 0.94X, 0.95X, 0.96X, 0.97X, 0.98X, 0.99X, 1.01X, 1.02X, 1.03X, 1.04X, 1.05X, 1.06X, 1.07X, 1.08X, 1.09X, and 1.10X. Thus, “approximately X” is intended to disclose, for example, “0.98X”. If “approximately” is applied to the beginning of a numerical range, it also applies to both ends of the range. If “approximately” is applied to the first value in a set of values, it applies to all values within that set.
[0037] The term "peptide" refers to a compound consisting of a single chain of D-amino acids or L-amino acids linked by peptide bonds, or a mixture of D-amino acids and L-amino acids. Generally, peptides have an amino acid length of about 2 to about 50. As non-limiting examples, peptides present in the conjugates described herein have an amino acid length of about 5 to about 45, about 8 to about 45, about 8 to about 25, about 8 to about 20, about 12 to about 45, about 12 to about 30, or about 20.
[0038] The term "RGD peptide" is α v This refers to the binding / interaction of peptide motifs in the conjugate described herein, which exhibits specific interaction ability with β6 integrin. In some embodiments, the RGD peptide does not cross-react with molecules of similar sequence or structure, α v It interacts with and / or binds to β6 integrin. In some cases, RGD peptides bind with a substantially lower dissociation constant (i.e., a stronger bond) than molecules with similar sequences or structures, α vIt specifically binds to β6 integrin. For example, in certain cases, the RGD peptide has an affinity of approximately 2, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 40, 50, 100, or more than 1000 times that of the related molecule. v When it binds to β6 integrin, specific binding occurs. RGD peptide α v Binding to β6 integrin can occur via intermolecular forces such as ionic bonds, hydrogen bonds, hydrophobic interactions, dipole bonds, and / or van der Waals forces. Cross-reactivity occurs, for example, α v This can be tested by evaluating the binding of RGD peptides to β6 integrins and a number of closely related molecules (e.g., structurally and / or functionally) under conventional conditions. These methods include, but are not limited to, binding studies, blocking and competition studies with closely related molecules, FACS analysis, surface plasmon resonance (using BIAcore, etc.), analytical ultracentrifugation, isothermal titration calorimetry, fluorescence anisotropy, fluorescence spectroscopy, radiolabeled ligand binding assays, and combinations thereof.
[0039] As used herein, the term “PEGylation” refers to the process of covalently bonding a polyethylene glycol (PEG) molecule to another molecule, such as an RGD peptide, and is subsequently referred to as “PEGylated.” As a non-limiting example, an RGD peptide may be PEGylated at both its amino and carboxyl terminals using a monodisperse PEG molecule of a specified chain length to produce a biterminally PEGylated peptide conjugate. Monodisperse PEG molecules typically contain distinct molecular weights with a precisely defined number of ethylene glycol repeating units. Suitable PEG moieties are commercially available from PolypureAS (Oslo, Norway), which supplies monodisperse PEG molecules and their PEG derivatives consisting of substantially only one oligomer (e.g., oligomer purity above approximately 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%). In certain embodiments, the RGD peptide is less than about 5,000 Datons (Da) (e.g., less than about 5,000, 4,000, or 3,000 Da), for example, PEG 11PEG 12 (PEG800), PEG 28 (PEG1500), and / or (PEG 28 Both ends are PEGylated by a monodisperse PEG moiety, either a single type or a mixture of different types, having a molecular weight such as 2(PEG1500×2).
[0040] The term "radionic nuclide" is intended to include all radioactive nuclides. "Nuclide" refers to carbon-14 ( 14 This refers to the type of atom identified by its atomic number, atomic mass, and energy state, such as C). "Radioactivity" refers to radiation emitted from radioactive materials, such as alpha particles, beta particles, nucleons, electrons, positrons, neutrinos, and gamma rays. Examples of radionuclides suitable for use in the conjugates described herein include tritium. 3 H), fluorine 18( 18 F), Lin32( 32 P), sulfur 35( 35 S), Scandium-47 ( 47 Sc), Cobalt 55 ( 55 Co), copper 60( 60 Cu), copper 61( 61 Cu), copper 62( 62 Cu), copper 64 ( 64 Cu), Gallium-66 ( 66 Ga), copper 67( 67 Cu), Gallium-67 ( 67 Ga), Gallium-68 ( 68 Ga), Rubidium-82 82 Rb), Yttrium 86 86 Y), Yttrium 87 87 Y), Strontium-89 ( 89 Sr), Strontium-90 90 Sr), Yttrium 90 90 Y), Rhodium 105 ( 105 Rh), Silver 111 ( 111 Ag), Indium-111 ( 111 In), Iodine-124 ( 124 I) Iodine-125 ( 125 I) Iodine-131 ( 131 I), Suzu 117m (117m tin (Sn), technetium 99m ( 99m Tc), cesium 137 ( 137 Cs), promethium 149 ( 149 Pm), samarium 153 ( 153 Sm), holmium 166 ( 166 Ho), lutetium 177 ( 177 Lu), rhenium 186 ( 186 Re), rhenium 188 ( 188 Re), thallium 201 ( 201 Tl), astatine 211 ( 211 At), astatine 215 ( 215 At), astatine 217 ( 217 At), astatine 218 ( 218 At), bismuth 209 ( 209 Bi), bismuth 211 ( 211 Bi), bismuth 212 ( 212 Bi), bismuth 213 ( 213 Bi), polonium 210 ( 210 Po), polonium 211 ( 211 Po), polonium 212 ( 212 Po), polonium 214 ( 214 Po), polonium 215 ( 215 Po), polonium 216 ( 216 Po), polonium 218 ( 218 Po), radon 218 ( 218 Rn), radon 219 ( 219 Rn), radon 220 ( 220 Rn), radon 222 ( 222 Rn), radon 226 ( 226 Rn), francium 221 ( 221 Fr), radium 223 ( 223 Ra), radium 224 ( 224 Ra), radium 226 ( 226 Ra), actinium 225 ( 225 Ac), actinium 227 ( 227 Ac), thorium 227 ( 227 Th), thorium 228 ( 228 Th), thorium 229 ( 229 Th), thorium 230 (230 Th), Thorium-232 ( 232 Th), Protactinium-231 ( 231 Pa), Uranium-233 ( 233 U), Uranium-234 ( 234 U), Uranium-235 ( 235 U), Uranium-236 ( 236 U), Uranium-238 ( 238 U), Neptunium-237 ( 237 Np), plutonium-238 ( 238 Pu), plutonium-239 ( 239 Pu), Plutonium-240 ( 240 Pu), Plutonium-244 ( 244 Pu), Americium-241 ( 241 Am), Curium 244 ( 244 Cm), Curium 245 245 Cm), Curium 248 ( 248 Cm), California 249 249 Cf), and California 252 252 Examples include, but are not limited to, Cf). 117m Sn and 99m The "m" in Tc represents the meta state. Furthermore, naturally occurring radioactive elements such as uranium, radium, and thorium, which are typically mixtures of radioactive isotopes, are good examples of radionuclides. 67 Cu, 131 I, 177 Lu, and 186 Re is a beta and gamma-emitting radionuclide. 212 Bi is a radioactive nuclide that emits alpha and beta rays. 226 Ra is a radioactive nuclide that emits alpha and gamma rays. 211 At, 215 At, 217 At 、218 At, 209 Bi, 211 Bi, 213 Bi, 210 Po, 211 Po, 212 Po, 214 Po, 215 Po, 216 Po,218 Po, 218 Rn, 219 Rn, 220 Rn, 222 Rn, 226 Rn, 221 Fr, 223 Ra, 224 Ra, 225 Ac, 227 Ac, 227 Th, 228 Th, 229 Th, 230 Th, 232 Th, 231 Pa, 233 U, 234 U, 235 U, 236 U, 238 U, 237 Np, 238 Pu, 239 Pu, 240 Pu, 244 Pu, 241 Am, 244 Cm, 245 Cm, 248 Cm, 249 Cf, and 252 Cf is an example of an alpha-emitting radionuclide. 3 H, 32 P, 35 S, 47 Sc, 89 Sr, 90 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 149 PM, 153 Sm, 166 Ho, and 188 Re is an example of a beta-emitting radionuclide. 67 Ga, 111 In, 99m Tc, 137 Cs, and 201 Tl is an example of a gamma-ray emitting radionuclide. 55 Co, 60 Cu, 61 Cu, 62 Cu, 66 Ga, 68 Ga, 82 Rb, and86 Y is an example of a positron-emitting radionuclide. 64 Cu is a radioactive nuclide that emits beta and positrons.
[0041] The terms “subject” or “patient” typically refer to humans, but may also include other animals such as other primates, rodents, dogs, cats, horses, sheep, and pigs.
[0042] As used herein, the term “administer” means oral administration, suppository administration, topical contact, intravenous, parenteral, intraperitoneal, intramuscular, intrafocal, intrathecal, intracranial, intranasal, or subcutaneous administration, or implantation into a target of a continuous release device, such as a miniature osmotic pump. Administration is by any route, including parenteral and transmucosal (e.g., cheek, sublingual, palate, gingiva, nose, vagina, rectum, or percutaneous). Parenteral administration includes, for example, intravenous, intramuscular, intraarteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial. Other delivery methods include, but are not limited to, the use of liposomal formulations, intravenous infusion, and transdermal patches. “Conjugate administration” means that the conjugate described herein is administered simultaneously with, immediately before, or immediately after the administration of a second drug.
[0043] III. RGD peptides and conjugates This specification provides a PRRT method using a therapeutic conjugate for PRRT, wherein the conjugate is α v It binds to β6 integrin. The conjugate used in the method herein is α vIt includes an RGD peptide that is selective for binding to β6 integrin. In some embodiments, the peptide comprises an RGD motif, RGDLX1X2X3, wherein X1 and X2 are independently selected amino acids and X3 is L or I. In certain embodiments, the RGD peptide does not contain alanine residues. In specific embodiments, the RGD peptide is 8 to 40 amino acids. In some cases, the RGD peptide is more than 20 amino acids. In some cases, the RGD peptide is 21 amino acids. In specific embodiments, the RGD peptide further comprises QX4VX5RT located at the C-terminus of the RGD motif, wherein X4 is R or K and X5 is A or G. In some cases, the RGD peptide contains the amino acid sequence QRVGRT located at the C-terminus of the RGD motif. In some cases, the RGD peptide contains the amino acid sequence RGDLQVLGQRVGRT. In specific embodiments, the RGD peptide contains the amino acid sequence GNGVPNLRGDLQVLGQRVGRT. In specific embodiments, the RGD peptide consists of or consists essentially of the amino acid sequence GNGVPNLRGDLQVLGQRVGRT.
[0044] In some embodiments, the conjugate also includes one or more polyethylene glycol (PEG) moieties covalently attached to the RGD peptide. In some cases, the conjugate contains two PEG moieties, for example, one PEG moiety is covalently attached to the N-terminus of the peptide and one PEG moiety is covalently attached to the C-terminus of the peptide. In specific embodiments, the conjugate contains the amino acid sequence GNGVPNLRGDLQVLGQRVGRT having a first PEG moiety covalently attached to the N-terminus of the peptide and a second PEG moiety covalently attached to the C-terminus of the peptide. In some embodiments, the PEG moiety covalently attached to the C-terminus of the peptide terminates with an amide, carboxyl group, or hydroxyl group.
[0045] In some embodiments, the first PEG portion and the second PEG portion each have a molecular weight of less than about 5000 Da, for example, less than about 3000 Da. In certain embodiments, the first PEG portion and the second PEG portion are monodisperse PEG portions having a specified chain length. Non-limiting examples of PEG portions having a specified chain length include small monodisperse PEG molecules having an oligomeric purity of more than about 95%. In certain cases, the first PEG portion and the second PEG portion are PEG 11 PEG 12 (PEG800), PEG 28 (PEG1500), and (PEG 28 It is independently selected from the group consisting of )2 (PEG1500×2). In certain embodiments, the first PEG portion and the second PEG portion are the same. In certain embodiments, both the first PEG portion and the second PEG portion are PEG 28 (PEG1500). In certain embodiments, the conjugate comprises the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and the N-terminus and C-terminus of the peptide are covalently bonded to PEG, respectively. 28 It has a (PEG1500) portion (also referred to herein as "5G"). In some embodiments, PEG is covalently bonded to the C-terminus of the peptide. 28 The (PEG1500) portion is terminated with an amide, carboxyl, or hydroxyl group.
[0046] In some embodiments, the conjugate includes an albumin-binding moiety (ABM) covalently bound to the conjugate. The ABM can extend the half-life of the conjugate in serum, for example, when administered to a subject. In some embodiments, the ABM is covalently bound to the peptide, the first PEG moiety, or the second PEG moiety. In some embodiments, the ABM includes a linker, such as a peptide linker, covalently bound to the peptide, the first PEG moiety, or the second PEG moiety. In certain embodiments, the ABM includes 4-(4-iodophenyl)butyrate (IPA), or its homologues having shorter alkyl chains, such as 4-(4-iodophenyl)propionic acid or 4-(4-iodophenyl)acetic acid, or the ABM includes 4-(4-methylphenyl)butyrate or 4-(4-bromophenyl)butyrate, or its homologues having shorter alkyl chains, such as propionic acid or its acetate homologue. In certain embodiments, the ABM is covalently bonded to the first and / or second PEG moiety via a linker such as a glutamic acid (E) linker, a peptide linker such as lysine-aspartic acid-aminobutyric acid (KD-Abu), or other suitable linkers known to those skilled in the art (e.g., amino acid or peptide linkers). In certain embodiments, the ABM comprises an ε-(4-(4-iodophenyl)butylamide)lysine-glutamic acid moiety ("K(IPA)E"), which corresponds to IPA covalently bonded to the side chain of the lysine residue of the lysine-glutamic acid peptide linker. In certain other embodiments, the ABM comprises a K(D-Abu-iodophenylbutyryl) moiety, which corresponds to IPA covalently bonded to aminobutyric acid of the lysine-aspartic acid-aminobutyric acid (KD-Abu) peptide linker. In some embodiments, the ABM comprising the K(IPA)E or K(D-Abu-iodophenylbutyryl) moiety is covalently bonded to the first PEG moiety. In certain embodiments, the conjugate comprises the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, where the N-terminus and C-terminus of the peptide are covalently bonded to it by PEG, respectively. 28It has a PEG moiety such as a (PEG1500) moiety, and the conjugate further includes a covalently attached ABM. In some embodiments, the PEG moiety covalently attached to the C-terminus of the peptide ends with an amide, carboxyl group, or hydroxyl group.
[0047] In other embodiments, the contrast agent or therapeutic agent is covalently attached (e.g., via a moiety family, chelator, or linker) to an albumin-binding motif that is covalently attached to a first PEG moiety such that the contrast agent or therapeutic agent is the most N-terminal moiety of the conjugate. In certain embodiments, the conjugate includes a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and the N-terminus and C-terminus of the peptide each have a PEG covalently attached thereto 28 It has a PEG moiety such as a (PEG1500) moiety, the ABM is covalently attached to the PEG moiety at the N-terminus of the peptide, and the therapeutic agent is covalently attached to the N-terminus of the conjugate. In certain embodiments, the conjugate includes a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and the N-terminus and C-terminus of the peptide each have a PEG covalently attached thereto 28 It has a PEG moiety such as a (PEG1500) moiety, the ABM is covalently attached to the PEG moiety at the N-terminus of the peptide, and the contrast agent is covalently attached to the N-terminus of the conjugate. In some embodiments, the PEG moiety covalently attached to the C-terminus of the peptide ends with an amide, carboxyl group, or hydroxyl group.
[0048] In some embodiments, the conjugate is a therapeutic conjugate and includes a therapeutic agent. In some embodiments, the therapeutic agent is a radionuclide such as an alpha-emitting, beta-emitting, and / or gamma-emitting radionuclide. In some embodiments, the therapeutic conjugates herein 3 H 18 F 32 [[ID=1十八]]P 35 S 47 Sc 55 Co 60 Cu 61 Cu 62 Cu 64Dog, 66 Yes, 67 Dog, 67 Yes, 68 Yes, 82 Rb, 86 Y、 87 Y、 89 Mr. 90 Mr. 90 Y、 105 Rh, 111 At, 111 In, 124 I, 125 I, 131 I, 117m Sn, 99m Tc, 137 Cs, 149 Pm, 153 Sm, 166 Yes, 177 Hello, 186 Yes, 188 Yes, 201 Tl, 211 At, 215 At, 217 At, 218 At, 209 Be, 211 Be, 212 Be, 213 Be, 210 Po, 211 Po, 212 Po, 214 Po, 215 Po, 216 Po, 218 Po, 218 Mr. 219 Mr. 220 Mr. 222 Mr. 226 Mr. 221 Fr. 223 Yes, 224 Yes, 226 Yes, 225 And, 227 And, 227 Oh, 228 Oh, 229 Oh, 230 Oh, 232 Oh, 231 Dad, 233 Oh, 234 Oh, 235 Oh, 236 Oh, 238 Oh,237 Np, 238 Pu, 239 Pu, 240 Pu, 244 Pu, 241 Am, 244 Cm, 245 Cm, 248 Cm, 249 Cf, 252 It contains radionuclides such as Cf. In some embodiments, the therapeutic conjugates described herein are 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 PM, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, 212 Includes radionuclides such as Bi. In certain embodiments, the radionuclides are 177 Lu. In some embodiments, the conjugate has the structure of formula I, where 5G is a double-PEGylated RGD peptide. TIFF2023552383000007.tif61128
[0049] In some embodiments, the conjugate has the structure of formula I, where 5G is a double-PEGylated RGD peptide, and the RGD peptide has the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, for example PEG 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 It contains -C(O)NH2.
[0050] In certain embodiments, the conjugate comprises a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, where the N-terminus and C-terminus of the peptide are covalently bonded to it by PEG. 28The ABM has a PEG moiety such as the (PEG1500) moiety, and is covalently bonded to the N-terminal PEG moiety of the peptide and to a chelate moiety for complexing with a radionuclide. In some embodiments, the PEG moiety covalently bonded to the C-terminus of the peptide is terminated with an amide, carboxyl, or hydroxyl group. In some embodiments, the chelate moiety is a DOTA moiety (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) covalently bonded to the conjugate. In some embodiments, the chelate moiety of the conjugate does not complex with the radionuclide. In some embodiments, the chelate moiety of the conjugate complexes with the radionuclide. In some embodiments, the chelate moiety of the conjugate complexes with the radionuclide, and the radionuclide is 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 PM, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 It is selected for use as a therapeutic agent, such as Bi. In some embodiments, the chelate portion of the conjugate is complexed with the radionuclide, and the radionuclide is 177 It is Lu. In some embodiments, the chelate portion of the conjugate is complexed with a radionuclide, and the radionuclide is 11 C, 13 N, 15 O, 18 F, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 In, 124 I, 125I, or 131 Selected for use as a therapeutic agent such as I. In certain embodiments, the radionuclide is 68 It is Ga.
[0051] In certain embodiments, the conjugate comprises a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, where the N-terminus and C-terminus of the peptide are covalently bonded to it by PEG. 28 It has a PEG moiety, such as a (PEG1500) moiety, and a chelate moiety for complexing with a radionuclide. In some embodiments, the PEG moiety covalently bonded to the C-terminus of the peptide is terminated with an amide, carboxyl group, or hydroxyl group. In some embodiments, the chelate moiety is a DOTA moiety (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) covalently bonded to the conjugate. In some embodiments, the chelate moiety of the conjugate does not complex with the radionuclide. In some embodiments, the chelate moiety of the conjugate complexes with the radionuclide. In some embodiments, the chelate moiety of the conjugate complexes with the radionuclide, and the radionuclide is 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 PM, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 It is selected for use as a therapeutic agent, such as Bi. In some embodiments, the chelate portion of the conjugate is complexed with the radionuclide, and the radionuclide is 177 It is Lu. In some embodiments, the chelate portion of the conjugate is complexed with a radionuclide, and the radionuclide is 11 C, 13 N, 15 O, 18 F, 55 Co,60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 In, 124 I, 125 I, or 131 Selected for use as a therapeutic agent such as I. In certain embodiments, the radionuclide is 68 It is Ga.
[0052] In some embodiments, therapeutic conjugates, such as the conjugate of formula I, are provided as a pharmaceutical composition for administration. In some cases, the pharmaceutical composition comprises one or more unit doses, the amount of radioactivity present in one dose being about 25 mCi to about 200 mCi. In certain embodiments, the amount of radioactivity present in one dose of the conjugate is about 25 mCi to about 50 mCi, about 25 mCi to about 100 mCi, about 25 mCi to about 150 mCi, about 25 mCi to about 200 mCi, about 50 mCi to about 100 mCi, about 50 mCi to about 150 mCi, about 50 mCi to about 200 mCi, about 100 mCi to about 150 mCi, about 100 mCi to about 200 mCi, or about 150 mCi to about 200 mCi. In some cases, the amount of radioactivity present in one unit dose is about 25 mCi, about 50 mCi, about 100 mCi, about 150 mCi, or about 200 mCi. In some embodiments, the amount of peptide in each unit dose of the conjugate is about 500 μg, about 400 μg, about 300 μg, about 200 μg, or about 100 μg of peptide or less. In some cases, the amount of peptide in each unit dose of the conjugate is about 100 μg of peptide or less.
[0053] In some embodiments, the conjugate is a diagnostic conjugate and comprises a diagnostic agent. In some embodiments, the diagnostic agent is a radionuclide such as a positron-emitting radionuclide. In some embodiments, the diagnostic conjugate of this specification is 11 C, 13 N, 15O, 18 F, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 In, 124 I, 125 I, or 131 Includes radioactive nuclides such as 1. In certain embodiments, the radioactive nuclides are 68 It is Ga. In some embodiments, the conjugate has the structure of formula II, where 5G is a double-PEGylated RGD peptide comprising the amino acid sequence GNGVPNLRGDLQVLGQRVGRT. TIFF2023552383000008.tif51128
[0054] IV.How to use The methods described herein include providing a therapeutic conjugate in a therapeutically effective dose as described herein. The therapeutic conjugate described herein is 177 It may contain radionuclides such as Lu. In some embodiments, the conjugate has the structure of formula I, where 5G is a double-PEGylated RGD peptide. In some embodiments, the RGD peptide (i.e., found within the conjugate having the structure of formula I) is an amino acid sequence GNGVPNLRGDLQVLGQRVGRT, for example PEG 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 It contains -C(O)NH2. TIFF2023552383000009.tif61128
[0055] In some embodiments, the dose of the therapeutic conjugate administered to the subject contains approximately 25 mCi to approximately 200 mCi of radioactivity. In some embodiments, the dose of the conjugate contains approximately 25 mCi to approximately 100 mCi of radioactivity. In some embodiments, the dose of the therapeutic conjugate contains approximately 25 mCi to approximately 150 mCi of radioactivity. In some cases, the administered dose contains approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi of radioactivity. In some embodiments, the amount of peptide in the dose of the therapeutic conjugate is approximately 500 μg, approximately 400 μg, approximately 300 μg, approximately 200 μg, or approximately 100 μg of peptide or less. In some cases, the amount of peptide administered in the dose of the therapeutic conjugate is approximately 100 μg of peptide or less. In some embodiments, the dose of the therapeutic conjugate does not cause adverse events (AEs), such as grade 3 or higher AEs (i.e., serious AEs), in the subject. In some embodiments, the dose of the therapeutic conjugate does not exceed approximately 23 Gy of radiation to the kidney and / or approximately 1.5 Gy of radiation to the bone marrow.
[0056] Therapeutic conjugates can be administered by infusion over a period of time, such as several minutes or several hours. In some embodiments, the therapeutic conjugate is infused over several minutes, for example, about 1 minute, 2 minutes, 5 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, 30 minutes, 35 minutes, 40 minutes, 45 minutes, or 55 minutes. In certain embodiments, the therapeutic conjugate is infused over approximately 30 minutes. In some embodiments, the therapeutic conjugate is infused over several hours, such as about 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, or 8 hours. In certain embodiments, the therapeutic conjugate is infused over approximately 4 hours. In some embodiments, the therapeutic conjugate is infused simultaneously with an amino acid solution. In some cases, the infusion of the amino acid solution is started before the infusion of the therapeutic conjugate.
[0057] In some embodiments, the therapeutic conjugate is administered to the subject one, two, three, four, or five times throughout the course of treatment. Subsequent administrations of the therapeutic conjugate may be given at predetermined time intervals, divided into days, weeks, or months. In some cases, if the tumor or cancerous cells recur, continue to grow, or are not completely cured after the initial administration of the therapeutic conjugate, the therapeutic conjugate is administered again. In some cases, if the subject does not show a complete response to the first treatment, or experiences a partial response, a stable response, or progressive disease, the therapeutic conjugate is administered again.
[0058] In some embodiments, the dosimetry and / or biodistribution of the therapeutic conjugate are evaluated after administration of the therapeutic conjugate to the subject. In non-limiting examples, the dosimetry and biodistribution of the therapeutic conjugate may be evaluated using nuclear imaging one day and / or seven days after administration (e.g., infusion) to the subject. In some cases, approximately 24 hours and / or 168 hours after administration of the therapeutic conjugate, the subject undergoes whole-body planar imaging (e.g., anterior and posterior views) and single-photon emission computed tomography / computed tomography (SPECT / CT) (e.g., extending through the perineum and ending at the proximal femur, at the apex of the skull, approximately 2-4 bed positions). In some cases, serial blood samples are taken approximately 5, 15, 30, 60, 120, and / or 180 minutes after administration of the therapeutic conjugate, for example, to evaluate biodistribution. In some cases, a complete chemistry, hematology, liver function tests, and / or electrocardiogram may be performed 1 and / or 7 days (e.g., ±48 hours) after administration of the therapeutic conjugate.
[0059] Methods of dosimetry and analysis are known in the art and include, but are not limited to, descriptive statistics reported for AUC based on the radioactivity-time curve of the therapeutic conjugate (e.g., mean, median, standard deviation, etc.) (e.g., individually for identifiable thoracic and abdominal organs, target lesions, and blood), maximum intake in target lesions and identifiable organs (e.g., achieved in %), specific absorbed dose per organ (μGy / MBq), and cumulative absorbed organ dose (Gy). In some cases, organs that received the highest absorbed dose, as assessed by equivalent dose to tissue, are summarized in a table using frequency and percentage. In some cases, graphic tools are used to illustrate the endpoints.
[0060] In some embodiments, the distribution of therapeutic conjugates is determined using whole-body planar SPECT / CT imaging. In non-limiting examples, absorbed radiation doses to the kidneys, stomach, uninvolved liver, bone marrow, and the whole body, as well as other organs showing accumulation of therapeutic conjugates, are calculated based on sequential blood counts and SPECT / CT scan analysis. In some cases, SPECT / CT images are used to calculate volume absorbed radiation doses for affected and healthy tissues; for example, radioactivity-time curves for normal tissue can be generated from region of interest (ROI) analysis from SPECT / CT scans, radioactivity-time curves for red bone marrow and heart can be generated from blood radioactivity concentrations measured by a well-scintillation counter, and / or volume of interest (VOI) can be generated for each patient. In some cases, the radioactivity concentration in red bone marrow is the same as the radioactivity concentration in the blood. In some cases, the radioactivity-time curves are integrated (e.g., analytically or numerically as needed) to obtain an AUC value that generates a so-called residence time. In some cases, this data is entered into organ dosimetry software (such as OLINDA / EXM) to generate estimated absorbed doses for normal tissue. In some cases, supplemental dosimetry assessments are performed, including, for example, lesion absorbed dose estimation based on image ROI analysis. In some cases, the absorbed dose is normalized to the administered radioactivity and expressed in mGy / MBq.
[0061] In some embodiments, the distribution of therapeutic conjugates in the target tumor (e.g., primary tumor or cancerous lesion), blood, gallbladder, liver, heart, lungs, spleen, kidneys, pancreas, stomach, small intestine, bladder, skin, muscle, bone, large intestine, and / or brain is determined, for example, using SPECT / CT imaging. In certain embodiments, the amount of therapeutic conjugate present in non-tumor tissue 24, 48, or 72 hours after administration is less than the amount of therapeutic conjugate present in non-tumor tissue 1 hour after administration. In certain embodiments, the ratio of therapeutic conjugate in tumor to therapeutic conjugate in non-tumor tissue 24, 48, or 72 hours after administration is higher than the ratio of therapeutic conjugate in tumor to therapeutic conjugate in non-tumor tissue 1 hour after administration.
[0062] In some embodiments, the amount of therapeutic conjugate present in kidney tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is less than the amount of therapeutic conjugate present in kidney tissue 1 hour after administration of the conjugate. In some embodiments, the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in kidney tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is higher than the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in kidney tissue 1 hour after administration of the conjugate.
[0063] In some embodiments, the amount of therapeutic conjugate present in gastric tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is less than the amount of therapeutic conjugate present in gastric tissue 1 hour after administration of the conjugate. In some embodiments, the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in gastric tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is higher than the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in gastric tissue 1 hour after administration of the conjugate.
[0064] In some embodiments, the amount of therapeutic conjugate present in the colorectal tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is less than the amount of therapeutic conjugate present in the colorectal tissue 1 hour after administration of the conjugate. In some embodiments, the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in the colorectal tissue 24 hours, 48 hours, and / or 72 hours after administration of the conjugate is higher than the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in the colorectal tissue 1 hour after administration of the conjugate.
[0065] In some embodiments, the amount of therapeutic conjugate in liver tissue is minimal when assayed at 1 hour, 24 hours, 48 hours, and / or 72 hours after administration of the conjugate. In some embodiments, the amount of therapeutic conjugate in the primary tumor is substantially greater than the amount of therapeutic conjugate in liver tissue at 1 hour, 24 hours, 48 hours, and / or 72 hours after administration of the conjugate.
[0066] In some embodiments of the methods described herein, a diagnostic conjugate is administered to the subject before the administration of a therapeutic conjugate. The diagnostic conjugate is an α (directly or indirectly) covalently bonded to a radionuclide. vIt contains an RGD peptide that binds to β6 integrin. In some cases, the RGD peptide of the diagnostic conjugate has the same amino acid sequence as the RGD peptide present in the therapeutic conjugate. In some embodiments, the radionuclide of the diagnostic conjugate may have a shorter half-life compared to the radionuclide of the therapeutic conjugate. In some cases, the radionuclide is 68 Ga. In some cases, the radionuclide of the diagnostic conjugate is 68 Ga, and the therapeutic conjugate contains the radionuclide 177 Lu. In some embodiments, the diagnostic conjugate has the structure of Formula II. TIFF2023552383000010.tif51128
[0067] In some embodiments, the diagnostic conjugate has the structure of Formula II, wherein 5G is a dual-PEGylated RGD peptide. In some embodiments, the RGD peptide (i.e., found within the diagnostic conjugate having the structure of Formula II) has the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, for example PEG 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 -C(O)NH2.
[0068] In some embodiments, the method includes administering a diagnostic conjugate of Formula II for the imaging diagnosis of tumors, cancerous lesions or cancer cells. In some embodiments, the method includes administering a diagnostic conjugate of Formula II for the imaging diagnosis of tumors, cancerous lesions or cancer cells and then administering a therapeutic conjugate of Formula I for treating the tumors, cancerous lesions or cancer cells. In some embodiments, the method includes administering a therapeutic conjugate of Formula I for treating a cancerous lesion when sufficient lesion uptake of the diagnostic conjugate of Formula II (e.g., any visualized lesion having a maximum standardized uptake value (SUVmax) greater than twice that of normal lung or liver) is detected.
[0069] In some embodiments, the diagnostic conjugate is administered to the subject by injection. In some embodiments, the diagnostic conjugate is administered by infusion. In some embodiments, the diagnostic conjugate is infused over a period of several minutes, for example, about 1 minute, 2 minutes, 3 minutes, 4 minutes, 5 minutes, 6 minutes, 7 minutes, 8 minutes, 9 minutes, 10 minutes, 15 minutes, 20 minutes, 25 minutes, or 30 minutes or less. In some embodiments, the diagnostic conjugate is infused over a period of about 5 minutes or less.
[0070] In some embodiments, the diagnostic conjugate can be imaged in the body or part of the body of the subject. In some embodiments, the uptake and accumulation of the diagnostic conjugate in a lesion, tissue, or organ can be used to select the target for administration of the therapeutic conjugate. In some embodiments, the diagnostic conjugate is α v It is used to select patients who have β6 integrin-related lesions or cancer cells and who are eligible for treatment with a therapeutic conjugate. In some embodiments, the diagnostic conjugate is used to select α v Patients with β6 integrin-related lesions or cancer cells are selected, and then the selected patients are administered a certain dose of a therapeutic conjugate, such as a therapeutic conjugate of formula I, within 1, 2, 3, 4, 5, or 6 weeks after imaging the diagnostic conjugate. In some embodiments, the diagnostic conjugate is used to α v Patients with β6 integrin-related lesions or cancer cells are selected, and then, within 4 to 5 weeks of imaging the diagnostic conjugate, a certain dose of a therapeutic conjugate, such as the therapeutic conjugate of formula I, is administered to the selected patients.
[0071] In some embodiments, the general distribution of diagnostic conjugates is determined by visual analysis of blood data and PET / CT scans. In a non-limiting example, reconstructed PET / CT images (e.g., static images of the entire body from the apex of the skull to the proximal femur) can be displayed on an imaging workstation and reoriented into maximum intensity projection (MIP) images, transaxial images, coronal images, and sagittal images. In certain embodiments, PET images, fused PET / CT images, and / or CT images are examined. In some embodiments, regions of interest (ROIs) are positioned around tracer-accumulating lesions suspected of being malignant and vital organs (e.g., kidneys, bladder, intestines, liver, spleen, lungs, pancreas) to obtain SUV parameters, including maximum and mean SUVs. In certain cases, SUV measurements are summarized using mean, median, range, and counts, and repeated measures ANOVA models are used to correlate SUVs to tissue regions. In some embodiments, "non-excreting" and "excreting" radioactivity are tracked, and non-excreting radioactivity in the body is calculated from volume of interest (VOI) analysis to derive the amount of radioactivity in major organs, tissues of interest, and the rest of the body. In some cases, the data are adjusted to a "ReferenceMan" anthropomorphic model for dosimetry purposes. In some cases, organ activity is integrated over time to obtain a time-integrated activity coefficient. In some cases, organ dosimetry software (such as OLINDA / EXM) is used to obtain dose and effective dose measurements.
[0072] Any apparatus or method known in the art for detecting the radioactive emission of radionuclides in a subject is suitable for use with the conjugates and methods described herein. Examples include single-photon emission computed tomography (SPECT), which uses a rotating gamma camera to detect radiation from single-photon gamma-ray radionuclides, and radionuclide scintigraphy (which acquires an image of the nuclide distribution or a series of sequential images). Radionuclides in tissues, organs, or body systems using a scintillation gamma camera can be used to detect radiation emitted from the radiolabeled conjugates described herein. Positron emission tomography (PET) is another suitable technique for detecting radiation within a subject. Furthermore, U.S. Patent No. 5,429,133 describes a laparoscopic probe for detecting radiation concentrated within solid tissue tumors. Small, flexible radiation detectors intended for medical use are manufactured by Intra-Medical LLC (Santa Monica, CA). Furthermore, methods based on nuclear magnetic resonance (NMR) (e.g., magnetic resonance spectroscopy (MRS) and magnetic resonance imaging (MRI)), or any other imaging technique known to those skilled in the art (including but not limited to computed tomography (CT)), can be combined with methods suitable for detecting the radioactive emission of radionuclides. In some embodiments, radiation from radionuclides is used to determine where a conjugate, such as the diagnostic conjugate described herein, is concentrated within a body of study. Regardless of the method or apparatus used, such detection is aimed at determining where the conjugate is concentrated within a body of study, and such concentration serves as an indicator of the location of a tumor or tumor cells.
[0073] In some embodiments, the therapeutic conjugate is used to treat cancer, for example, α vIt is administered to subjects suffering from β6 integrin-related cancers. Non-limiting examples of different types of cancer suitable for treatment with the therapeutic conjugate described herein include lung cancer, breast cancer, pancreatic cancer, bladder cancer, thyroid cancer, liver cancer, pleural cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, testicular cancer, colon cancer, colorectal cancer, anal cancer, bile duct cancer, gastrointestinal carcinoid tumors, esophageal cancer, gallbladder cancer, rectal cancer, appendiceal cancer, small intestine cancer, stomach cancer, kidney cancer (i.e., renal cell carcinoma), and middle-grade cancer. Examples include central nervous system cancers, skin cancers, oral squamous cell carcinoma, cutaneous squamous cell carcinoma, choriocarcinoma, head and neck cancers, bone cancers, osteogenic sarcomas, fibrosarcomas, neuroblastomas, gliomas, melanomas, leukemias (e.g., acute lymphoblastic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, or hairy cell leukemia), lymphomas (e.g., non-Hodgkin lymphoma, Hodgkin lymphoma, B-cell lymphoma, or Burkitt lymphoma), and multiple myeloma. In some embodiments, the cancer is pancreatic cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, cutaneous squamous cell carcinoma, gastric cancer, or endometrial cancer. In some cases, the subject has a primary site (e.g., a primary tumor). In some cases, the subject has metastases (e.g., any metastatic form of any of the cancer types described herein). In some cases, the subject has both a primary site and metastases. In some embodiments, the subjects have locally advanced or metastatic pancreatic cancer; locally advanced, unresectable, or metastatic pancreatic adenocarcinoma; or pancreatic ductal adenocarcinoma (PDAC) or other pancreatic cancers.
[0074] In some embodiments, the subject receives a therapeutic conjugate of Formula I containing a dose of radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose having radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, administered over several minutes or several hours, for example, approximately 1 minute, approximately 2 minutes, approximately 5 minutes, approximately 10 minutes, approximately 15 minutes, approximately 20 minutes, approximately 25 minutes, approximately 30 minutes, approximately 35 minutes, approximately 40 minutes, approximately 45 minutes, approximately 55 minutes, approximately 1 hour, approximately 2 hours, approximately 3 hours, approximately 4 hours, approximately 5 hours, approximately 6 hours, approximately 7 hours, or approximately 8 hours. In certain embodiments, the subject receives a therapeutic conjugate of Formula I containing a dose of radioactivity ranging from approximately 25 mCi to approximately 200 mCi, such as a dose having radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, administered over a period of approximately 30 minutes.
[0075] In some embodiments, the subject receives standard treatment before administration of a dose of the therapeutic conjugate. In some embodiments, the therapeutic conjugate has the structure of formula I, and the subject receives a dose of the therapeutic conjugate containing radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, and the subject receives standard treatment before such a dose. In some embodiments, the standard treatment includes one or more of surgery, radiotherapy, chemotherapy, chemoradiotherapy, and targeted therapy. The standard treatment may include FOLFIRINOX (leucovorin calcium (folic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin). The standard treatment may include gemcitabine, Abraxane, or a combination thereof. The standard treatment may include irinotecan. Standard treatment may include surgery, or surgery with one or more of the following: FOLFIRINOX, gemcitabine, Abraxane, and irinotecan.
[0076] In some embodiments, the subject receives standard treatment after administration of a dose of the therapeutic conjugate. In some embodiments, the therapeutic conjugate has the structure of formula I, and the subject receives a dose of the therapeutic conjugate containing radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, after which the subject receives standard treatment. In some embodiments, standard treatment includes one or more of surgery, radiotherapy, chemotherapy, chemoradiotherapy, and targeted therapy. Standard treatment may include FOLFIRINOX (leucovorin calcium (folic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin). Standard treatment may include gemcitabine, Abraxane, or a combination thereof. Standard treatment may include irinotecan. Standard treatment may include surgery, or surgery with one or more of the following: FOLFIRINOX, gemcitabine, Abraxane, and irinotecan.
[0077] In some embodiments, the subject receives one or more standard treatments before and after administration of a dose of the therapeutic conjugate. In some embodiments, the therapeutic conjugate has the structure of formula I, and the subject receives a dose of the therapeutic conjugate containing radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, and the subject receives standard treatment both before and after such a dose. In some embodiments, the standard treatment includes one or more of surgery, radiotherapy, chemotherapy, chemoradiotherapy, and targeted therapy. The standard treatment may include FOLFIRINOX (leucovorin calcium (folic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin). The standard treatment may include gemcitabine, Abraxane, or a combination thereof. The standard treatment may include irinotecan. Standard treatment may include surgery, or surgery with one or more of the following: FOLFIRINOX, gemcitabine, Abraxane, and irinotecan. Standard treatment before and after treatment with a therapeutic conjugate may be the same. Standard treatment before and after treatment with a therapeutic conjugate may differ from each other.
[0078] In some embodiments, treatment with a therapeutic conjugate results in stable disease, partial remission, or complete remission in a subject (for example, the method described herein involves administering a dose of a therapeutic conjugate that kills cancer cells or otherwise slows their growth or progression, resulting in stable disease or partial or complete remission of cancer in a subject). In some embodiments, treatment with a therapeutic conjugate results in a reduction of cancer metastasis in a subject (for example, the method described herein involves administering a dose of a therapeutic conjugate to a subject that reduces cancer metastasis in a subject). In some embodiments, treatment with a therapeutic conjugate results in a reduction of tumor volume, size, or growth in a subject (for example, the method described herein involves administering a dose of a therapeutic conjugate to a subject that reduces tumor volume, size, or growth in a subject). In some embodiments, treatment with a therapeutic conjugate results in an increased response of cancer to subsequently administered anticancer drugs (for example, the method described herein involves administering a subject to a dose of a therapeutic conjugate that increases its response to subsequently administered anticancer drugs).
[0079] In some embodiments, a subject is treated with a therapeutic conjugate of formula I, the subject receiving a dose of the therapeutic conjugate containing radioactivity ranging from approximately 25 mCi to approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, and the treatment with the therapeutic conjugate results in stable disease, partial remission, or complete remission in the subject (for example, administration of the therapeutic conjugate kills cancer cells or otherwise slows their growth or progression, resulting in stable disease or partial or complete remission of cancer in the subject).
[0080] In some embodiments, a subject is treated with a therapeutic conjugate of formula I, and the subject receives a dose of the therapeutic conjugate containing radioactivity ranging from about 25 mCi to about 200 mCi, such as a dose with radioactivity of about 25 mCi, about 50 mCi, about 100 mCi, about 150 mCi, or about 200 mCi, and treatment with the therapeutic conjugate reduces cancer metastasis in the subject (for example, administration of the therapeutic conjugate reduces cancer metastasis in the subject).
[0081] In some embodiments, a subject is treated with a therapeutic conjugate of formula I, the subject receiving a dose of the therapeutic conjugate containing radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, the treatment with the therapeutic conjugate reduces the volume, size, or growth of tumors in the subject (for example, administration of the therapeutic conjugate reduces the volume, size, or growth of tumors in the subject).
[0082] In some embodiments, subjects are treated with a therapeutic conjugate of formula I, where the subjects receive a dose of the therapeutic conjugate containing radioactivity ranging from approximately 25 mCi to approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi, and treatment with the therapeutic conjugate results in an increased response of the cancer to subsequently administered anticancer drugs (for example, administration of the therapeutic conjugate increases the response of the cancer to subsequently administered anticancer drugs).
[0083] In some embodiments, the subject has locally advanced, unresectable, or metastatic pancreatic adenocarcinoma, and the subject is treated with a therapeutic conjugate of formula I, the subject receiving a dose of the therapeutic conjugate containing radioactivity between approximately 25 mCi and approximately 200 mCi, such as a dose with radioactivity of approximately 25 mCi, approximately 50 mCi, approximately 100 mCi, approximately 150 mCi, or approximately 200 mCi. In some embodiments, the treatment results in stable disease, partial remission, or complete remission in the subject (e.g., administration of the therapeutic conjugate kills cancer cells or otherwise slows their growth or progression, resulting in stable disease or partial remission or complete remission of the cancer in the subject). In some embodiments, the treatment results in a reduction of metastasis of pancreatic cancer in the subject (e.g., administration of the therapeutic conjugate reduces metastasis of cancer in the subject). In some embodiments, the treatment results in a reduction of the volume, size, or growth of pancreatic tumors in the subject (e.g., administration of a therapeutic conjugate reduces the volume, size, or growth of tumors in the subject). In some embodiments, the treatment results in an increased response of cancer to subsequently administered anticancer agents, such as chemotherapeutic agents or combinations thereof (e.g., administration of a therapeutic conjugate increases the response of cancer to subsequently administered anticancer agents). In some embodiments, the treatment results in an increased response of cancer to subsequently administered anticancer agents, such as FOLFIRINOX, gemcitabine, Abraxane, irinotecan, or any combination thereof.
[0084] V. Pharmaceutical Compositions The therapeutic and diagnostic conjugates described herein can be formulated as pharmaceutical compositions for use. Such pharmaceutical compositions may comprise a conjugate and one or more pharmaceutically acceptable excipients suitable for injection and / or infusion.
[0085] The conjugates described herein can be formulated as compositions for administration in liquid form. These liquids may be useful for delivery by injection, such as intratumoral injection or intravenous infusion. Compositions for injection may also include one or more of the following: surfactants, preservatives, wetting agents, dispersants, suspending agents, buffers, stabilizers (e.g., radioprotective agents), and isotonic agents.
[0086] Liquid compositions, whether in solution, suspension, or other similar forms, may include one or more of the following: sterile diluents such as water for injection, saline, preferably physiological saline, Ringer's solution, and isotonic sodium chloride; fixing oils such as synthetic mono or diglycerides, polyethylene glycol, glycerin, cyclodextrin, propylene glycol, or other solvents that function as solvents or suspension media; antimicrobial agents such as benzyl alcohol and methylparaben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as amino acids, acetates, citrates, or phosphates; detergents such as nonionic surfactants and polyols; and agents for adjusting tonicity, such as sodium chloride or glucose. Liquid compositions may also include aqueous or oily suspensions, or emulsions with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or sterile aqueous solutions, and similar pharmaceutical vehicles. Aqueous solutions in physiological saline may also be conventionally used for injection. Ethanol, glycerol, propylene glycol, and liquid polyethylene glycol (and suitable mixtures thereof), cyclodextrin derivatives, and vegetable oils may also be used. For example, in the case of dispersions, appropriate fluidity can be maintained by the use of coatings such as lecithin to maintain the required particle size, and by the use of surfactants.
[0087] The compositions for administration as described herein are preferably sterile. Inhibition of microbial activity can be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.
[0088] The compositions for administering conjugates as described herein generally comprise at least one excipient, such as water for infusion, a physiological salt solution (0.9% NaCl), or a cell buffer, and preferably consist of a physiological salt solution substituted with a protein component such as human serum albumin (HSA).
[0089] The conjugate composition for administration can be sealed in ampoules, disposable syringes, or multi-dose vials made of glass, plastic, or other materials.
[0090] In some cases, the diagnostic conjugate is formulated in a 0.9% sodium chloride solution of USP with anhydrous ethanol at 10% v / v or less. In some cases, the therapeutic conjugate is formulated in 5 mg / mL sodium ascorbate, USP in a 0.9% sodium chloride solution, and USP with anhydrous ethanol at 10% v / v or less. [Examples]
[0091] VI. Examples The following embodiments are provided to illustrate the subject matter of the claims and are not limiting.
[0092] Example 1: Therapeutic / Diagnostic Agent The synthesis of DOTA-5G (Formula II) and DOTA-ABM-5G (Formula I) was carried out using DOTA-Tris (tert-butyl ester) as a chelating agent, resulting in NOTA-K(ABM)-α vThis was carried out on a solid phase as previously described for β6-BP, which is disclosed in Hausner et al. “The Effects of an Albumin Binding Moiety on the Targeting and Pharmacokinetics of an Integrin alphavbeta6-Selective Peptide Labeled with Aluminum[(18)F]Fluoride”, Mol Imaging Biol 22, 1543-1552 (2020) ("Hausner 2020"), the entirety of which is incorporated herein by reference. Using 20% piperidine (v / v in DMF), a fully protected peptide (NovaBiochem) 5G (5G = PEG) was used. 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 After removing the N-terminal Fmoc protecting group from -NH2) (1 equivalent), DOTA-tris(tert-butyl ester) (CheMatech) (3 equivalents) was bonded using 1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxidehexafluorophosphate (HATU) (2.8 equivalents) and diisopropylethylamine (DIPEA) base (6 equivalents) in a solution of dimethylformamide (DMF). The protecting group was removed, and DOTA-α was removed from the resin using trifluoroacetic acid (TFA) / ethanedithiol / water / triisopropylsilane (94:2.5:2.5:1v / v / v / v). v β6-BP was cleaved at ambient temperature for 3 hours. The pure product was isolated using RP-HPLC (Beckman-Coulter-Gold HPLC) and characterized by matrix-assisted laser desorption / ionization (MALDI) mass spectrometry (Bruker): DOTA-5G, HPLC retention time (R t ) = 14.45 min; MALDIm / z = 5198.2, calculated value = 5199.1 [M+H]. DOTA-ABM-5G, HPLCR t =17.07 minutes. MALDIm / z analysis = 5786.1046, calculated value = M(C 251 H 457 IN 44 O 98)5783.1174, 5784.1252[M+H] + .
[0093] [ 68 Ga]GaDOTA-5G and [ 177 Lu]LuDOTA-ABM-5G was radiolabeled under cGMP conditions. 68 The final product of Ga]GaDOTA-5G (peptide mass less than 100 μg) (Equation II) contained approximately 185 MBq (5 mCi) of radioactivity. 68 Ga is used with 5 mL of 0.1 N HCl. 68 Ge / 68 The galvanic acid was eluted from Ga generators (Eckert and Ziegler) and used without further purification. Radiolabeling was performed in 1 MHEPES buffer at pH 4. DOTA-5G (45 μg) or DOTA-ABM-5G (50 μg) was added in the reaction vessel. 68 The mixture was mixed with GaCl3 (4.3 mCi). The mixture was heated at 90°C for 15 minutes, injected into an HPLC, and the peak of the purified product was collected. It was diluted with 15 mL of water and loaded into a C-18 SepPak Light cartridge. The cartridge was washed with water, and the final product was eluted with 1.5 mLEtOH. This final product was then dried at 50°C under nitrogen gas flow and formulated in PBS for use. The pure product was characterized by radioactive HPLC. 68 Ga]GaDOTA-5G for 9.13 minutes, 68 Ga]GaDOTA-ABM-5G was co-eluted with a cold standard at 9.6 minutes.
[0094] DOTA-5G (52 μg) or DOTA-ABM-5G (58 μg) in 100-150 μL of buffer and 25 μL of ascorbic acid (5 mg / mL) 177 By adding it to LuCl3 (5mCi), the peptides DOTA-5G and DOTA-ABM-5G are produced. 177Radiolabeling with Lu was performed in 0.1 M sodium acetate buffer at pH 5. The reaction vessel was heated at 95°C for 15 minutes. Radiochemical purity was monitored by i-TLC (TEC control / BIODEX, solvent phase: 0.1 M trisodium citrate) and the above-described radioactive HPLC method. The product was characterized by radioactive HPLC, [ 177 Lu]LuDOTA-5G in 16.39 minutes, [ 177 Lu]LuDOTA-ABM-5G was co-eluted with a cold standard for 17.82 minutes, and the final product was formulated in PBS for use.
[0095] [ 68 Ga]GaDOTA-5G and [ 68 Ga]GaDOTA-ABM-5G was obtained with a radiochemical purity (RCP) of over 98% after semi-preparative HPLC purification. The molar activity at the start of both reactions was 0.5 Ci / μmol. 177 Lu]LuDOTA-5G and [ 177 Lu]LuDOTA-ABM-5G was obtained with RCP of over 97%. The specific activity of both reactions was 0.5 Ci / μmol.
[0096] The product was used within approximately 120 minutes of preparation. 177 The final product (Formula I) of Lu]LuDOTA-ABM-5G (<100 μg peptide mass) contained approximately 925–7400 MBq (25–200 mCi) of radioactivity, generating doses of 25, 50, 100, 150, and 200 mCi in particular. After preparation, the product was used within approximately 6 hours of its formation. TIFF2023552383000011.tif61128DOTA=1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid ABM=K(D-ab-iodophenylbutyryl) portion 5G = PEG 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 -C(O)NH2 peptide
[0097] Example 2: In vitro IC 50 measurement 4-(p-iodophenyl)butyrate (IP)ABM was conveniently incorporated into peptide 1 using standard Fmoc-peptide chemistry. Integrin α v β6 and α v The competitive enzyme-linked immunosorbent assay (ELISA) for β3 is described in Hausner et al.'s "Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: Generation and evaluation of 4-[ 18 The procedure described above was followed, as disclosed in “F]fluorobenzoylA20FMDV2 for in vivo imaging of integrin alpha(v)beta(6) expression with positron emission tomography”Cancer Res. 2007;67:7833-40 (“Hausner 2007”), which is incorporated herein by reference in its entirety. The data were analyzed using Prism software (GraphPad Software, La Jolla, CA, USA).
[0098] α v For β6, the experiment was performed in triplicate using biotinylated latent-related peptide (G&P Biosciences, Santa Clara, CA, USA). Dried skim milk powder (Raley's, West Sacramento, CA, USA) was used instead of bovine serum albumin; the blocking buffer consisted of PBS containing 0.5% skim milk powder (w / v) and 1% Tween 20 (v / v); the conjugated buffer was prepared by adding 0.1% skim milk powder (w / v) to the wash buffer, as disclosed in Hausner 2007.
[0099] Integrin α measured by ELISA v The binding affinities of DOTA-5G and DOTA-ABM-5G to β6 were 35±1 nM and 27±4 nM, respectively (Figures 1A and 1B).50 As is evident from the values, this structural modification is integrin α v The affinity of peptide 2 for β6 was not impaired (Figure 2).
[0100] Example 3: In vitro cell binding, internal migration, and efflux. The cell line (ATCC) was analyzed by flow cytometry to confirm integrin expression levels. Hu et al., “Characterization and Evaluation of 64 Cu-Labeled A20FMDV2 Conjugates for Imaging the Integrin α v As disclosed in β6”, Mol Imaging Biol. 2014;16:567-77 (the whole of which is incorporated herein by reference), radioactive tracers [ 68 Ga]GaDOTA-5G and [ 177 Lu]LuDOTA-ABM-5G Integrin α v Binding to β6 and internal translocation into BxPC-3 cells were measured 60 minutes after incubation.
[0101] Assay tubes were pre-treated with skim milk powder (0.5% wt / v in PBS) to prevent nonspecific binding. 177 Samples from Lu]LuDOTA-ABM-5G were further analyzed to measure efflux after internal migration. The internal migration fraction (pellet) was suspended in 0.3 mL of serum-free RPMI, and the supernatant was collected at 0.25 hours and 1 hour, respectively. The pellet was then washed in another 0.3 mL of PBS. At each time point, the supernatant and washing solution were combined, and the pellet was suspended in 0.6 mL of PBS. The percentage of radioactivity retained in the pellet was measured using a gamma counter.
[0102] All radioactive tracers show alpha in 1 hour. v This study demonstrated binding to cells targeting β6 and internal translocation into cells. 68 Regarding Ga]GaDOTA-5G, 9.7±1.0% (of the total radioactivity) is α vIt bound to β6(+)BxPC-3 cells, and 6.1 ± 0.4% (of the total radioactivity) was internally transferred into the cells. 177 For Lu]LuDOTA-ABM-5G, 29±1.4% of the total radioactivity (21.6±0.01% internal migration) bound to BxPC-3 cells (Figure 1C), and a very small amount of leakage (5%) was observed after 1 hour (Figure 1D).
[0103] Example 4: In vitro albumin binding Radioactive tracer [ 177 Lu]LuDOTA-5G and [ 177 The binding of Lu]LuDOTA-ABM-5G to mouse and human serum proteins was evaluated by quad ultrafiltration using a Centrifree Ultrafiltration apparatus (Millipore Sigma) according to the manufacturer's recommendations, as disclosed in Hausner 2020. The apparatus was pre-treated with PBS containing Tween 20 (5% v / v) and subsequently washed three times with PBS, as disclosed in Hausner 2007. Aliquots (≤25 μL, 20–60 KBq) of each formulated radioactive tracer in PBS were thoroughly mixed with 0.5 mL of serum in a microcentrifuge tube at 37°C. The mixture was incubated at 37°C for 5 minutes, and an aliquot (50 μL) was transferred to a tube for gamma counting. The remaining sample was transferred to the Centrifree Ultrafiltration apparatus and centrifuged for 40 minutes at 1500 × g at ambient temperature (20–24°C). An aliquot (50 μL) of the filtrate was transferred to a tube for gamma counting. For each radioactive tracer, a blank was performed using 0.5 mL PBS / Tween20 (5% v / v) instead of serum (n=4), and nonspecific binding was measured. After γ-counting, protein-bound radioactivity was calculated by subtracting the count measured in the filtrate aliquot (i.e., unbound to proteins) from the count in the corresponding serum aliquot. The data are expressed as the mean ± standard deviation of the percentage of radioactivity bound to proteins after subtracting the nonspecific binding measured in the blank.
[0104] Albumin binding measured by ultrafiltration was found to be [177 Compared to 18.1±0.2% and 16.2±0.4% respectively for Lu]LuDOTA-5G, [ 177 For Lu]LuDOTA-ABM-5G, the results were 54.4±2.8% and 58.1±0.4%, respectively.
[0105] Example 5: In vitro serum stability Mouse or human serum (500 μl, both purchased from Millipore Sigma) was mixed with aliquots (100-200 μCi) of formulated radioactive tracer and incubated at 37°C. 68 In the case of Ga radioactive tracers, 1 hour and 2 hours after incubation, 177 In the case of Lu radioactive tracers, aliquots (100-200 μl) were taken for analysis 1 hour and 24 hours after incubation, mixed with anhydrous ethanol (500 μl, 4°C), and centrifuged (2300 × g, 3 minutes) to precipitate serum proteins. Hausner et al., “In vitro and in vivo evaluation of the effects of aluminum[ 18 F]fluoride radiolabeling on an integrin α v As disclosed in “β6-specific peptide” Nuclear medicine and biology. 2014;41:43-50 (the entire article is incorporated herein by reference), the supernatant was diluted with HPLC solvent A and analyzed by radioactive HPLC to determine the proportion of intact radioactive tracers.
[0106] [ 68 Ga]GaDOTA-5G, 68 Ga]GaDOTA-ABM-5G, [ 177 Lu]LuDOTA-5G, and [ 177 The stability of Lu]LuDOTA-ABM-5G was investigated in both mouse and human serum. All radiotracers showed some degree of degradation in mouse serum over time. In contrast, [ 68 Ga]GaDOTA-5G and [68 Both Ga]GaDOTA-ABM-5G were 100% stable in 2 hours, 177 Lu]LuDOTA-5G and [ 177 Lu]LuDOTA-ABM-5G was stable in human serum for over 24 hours with over 97% accuracy.
[0107] Example 6: In vivo imaging and in vivo distribution Female nu / nu nude mice (6-8 weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA) and handled according to the UC Davis Institutional Animal Care and Use Committee. 100 μl 1:1 GFR-Matrigel:BxPC-3 cells (5 × 10) in serum-free RPMI. 6 The cells were subcutaneously transplanted into the left shoulder flank and allowed to grow for approximately 2 weeks (for therapeutic research) and 3 weeks (0.5-1 cm in diameter, for imaging and in vivo distribution research). All cells were evaluated by flow cytometry before injection to confirm integrin expression levels. Food and water were allowed to be consumed freely.
[0108] For imaging of small animals, aliquots of formulated radioactive tracers (7.4–9.25 MBq per 100 μl) in PBS solution (pH 7.2) were intravenously (iv) into the tail vein of mice anesthetized with 2–3% isoflurane in medical-grade oxygen via catheter (n=3 / time point / radioactive tracer). Animals were lined up on the scanner bed in a prone position, feet first, and scanned two at a time. Anesthesia was maintained during scanning with 1.5–2.5% isoflurane in medical-grade oxygen. 68 Mice injected with Ga]GaDOTA-5G were scanned 2 hours post-injection (pi), and static 15-minute emission scans were acquired at 1 hour and 30 minutes post-injection. 68 Mice injected with Ga]GaDOTA-ABM-5G were scanned 4 hours after injection, and static 30-minute scans were acquired at 2 hours and 60 minutes. For attenuation correction... 57 Cobalt transmission scans and CT scans for anatomical reference were also acquired at each point in time. Representative images are shown in Figure 2.
[0109] For in vivo distribution, an aliquot of the formulated radioactive tracer (2.96-3.7 MBq in 100 μl of PBS) was injected into the tail vein, followed by 1 hour and 2 hours ([ 68 Ga]GaDOTA-5G), 2 hours and 4 hours ([ 68 Ga[GaDOTA-ABM-5G), and 1, 24, 48, and 72 hours ([ 177 Lu]LuDOTA-5G and [ 177 The mice were conscious when administered [Lu]LuDOTA-ABM-5G). In blocking studies, each unchelated cold peptide (30 mg / kg, 10 mg / mL (DOTA-5G) and 48 mg / kg, 16 mg / mL (DOTA-ABM-5G) solution in PBS) was injected 10 minutes before the combined radiotracer. At each time point, mice (n=3 / time point / radiotracer) were anesthetized and sacrificed. Tissue was collected, rinsed with PBS, and the radioactivity of each was measured using a gamma counter. Radioactivity concentrations were calibrated, decay-corrected, and expressed as a percentage of the injected volume per gram of tissue (%ID / g).
[0110] [ 68 Ga]GaDOTA-5G and [ 68 Ga]GaDOTA-ABM-5G was evaluated by in vivo imaging. 68 Ga]GaDOTA-5G, 68 Ga]GaDOTA-ABM-5G, [ 177 Lu]LuDOTA-5G, and [ 177 Lu]LuDOTA-ABM-5G was evaluated by its in vivo distribution within a subcutaneous BxPC-3 tumor model. 68 Imaging and in vivo distribution of Ga]GaDOTA-5G were performed at 1 hour and 2 hours after injection (pi), [ 68 Ga]GaDOTA-ABM-5G was administered 2 and 4 hours after injection. BxPC-3 tumor uptake was evident at all time points for both radiotracers.
[0111] Uptake of BxPC-3 in tumors is [68 For Ga]GaDOTA-5G, the percentage was 2.6±0.8% at 1 hour after injection and 2.03±0.6% at 2 hours, [ 68 For Ga]GaDOTA-ABM-5G, the blood glucose levels were 9.39±1.9% at 2 hours after injection and 10.35±2.6% at 4 hours (Figures 3A and 3B). 68 Ga]GaDOTA-5G and [ 68 The difference in uptake between Ga]GaDOTA-ABM-5G is reflected in the PET / CT images (Figure 2), and within the tumor [ 68 Uptake of Ga]GaDOTA-ABM-5G occurs 2 hours after injection. 68 It appears to be significantly higher than Ga]GaDOTA-5G.
[0112] [ 68 Ga]GaDOTA-5G and [ 68 The primary excretion route for both Ga]GaDOTA-ABM-5G was the kidneys. 68 For Ga]GaDOTA-5G, uptake was 23.34±3.31%ID / g at 1 hour, and decreased to 13.83±3.91%ID / g at 2 hours (p=0.032). 68 For Ga]GaDOTA-ABM-5G, uptake was 19.62±2.83%ID / g at 2 hours and increased to 25.92±2.24%ID / g at 4 hours (p=0.039) (Figures 3A and 3B, Table 1). 68 Regarding Ga]GaDOTA-5G, the BxPC-3 / kidney ratio increased slightly from 0.12±0.05 (1 hour) to 0.16±0.07 (2 hours), [ 68 For Ga]GaDOTA-ABM-5G, the value decreased slightly from 0.48±0.12 (2 hours) to 0.41±0.13 (4 hours) (both: p>0.05).
[0113] (Table 1) BxPC-3(α v In mice with β6(+) tumors [ 68 Ga]GaDOTA-5G and [ 68 In vivo distribution of Ga]GaDOTA-ABM-5G (n=3 / group / time point). TIFF2023552383000012.tif94165
[0114] In the blood [ 68 The circulation of Ga]GaDOTA-ABM-5G is increasing, 68 Compared to Ga]GaDOTA-5G, this was particularly observed by PET imaging at 2 hours (Figures 3A and 3B). This is also reflected in the in vivo distribution results, [ 68 Compared to Ga]GaDOTA-5G (0.09±0.01%ID / g), [ 68 In GaDOTA-ABM-5G, an 8-fold increase in %ID / g (8.89±0.89%ID / g) was observed in the blood after 2 hours. 68 The BxPC-3 / blood ratio for Ga]GaDOTA-5G increased from 12.92±0.73 at 1 hour to 22.05±3.86 at 2 hours (p=0.0158). 68 For Ga]GaDOTA-ABM-5G, the BxPC-3 / blood ratio was 1.06±0.22 at 2 hours and 1.94±0.12 at 4 hours (p=0.003).
[0115] The stomach and intestines are, 68 Ga]GaDOTA-5G and [ 68 Both Ga]GaDOTA-ABM-5G showed elevated radioactivity levels, and uptake in all organs was [ 68 Compared to Ga]GaDOTA-5G, 68 In GaDOTA-ABM-5G, the amount increased more than fourfold two hours after injection; %ID / g-stomach: 2.75±0.63([ 68 Ga]GaDOTA-5G) and 11.8±0.65([ 68 Ga]GaDOTA-ABM-5G), small intestine: 1.27±0.16([ 68 Ga]GaDOTA-5G) and 7.70±0.45([ 68 Ga]GaDOTA-ABM-5G), Large intestine: 2.08±0.21([ 68 Ga]GaDOTA-5G) and 8.73±0.11([ 68GaDOTA-ABM-5G) (Figures 3A and 3B, Table 1). The BxPC-3 / organ ratio obtained 2 hours after injection was BxPC-3 / stomach: 0.75 ± 0.23 ([ 68 Ga]GaDOTA-5G) and 0.88±0.25([ 68 Ga]GaDOTA-ABM-5G);BxPC-3 / small intestine:1.63±0.54([ 68 Ga]GaDOTA-5G) and 1.34±0.31([ 68 Ga]GaDOTA-ABM-5G);BxPC-3 / Colon:0.98±0.26([ 68 Ga]GaDOTA-5G) and 1.18±0.29([ 68 The result was Ga]GaDOTA-ABM-5G). The BxPC-3 / liver ratio was [ 68 Ga]GaDOTA-5G is 19.64±6.65, 68 The result for Ga]GaDOTA-ABM-5G was 6.04±0.91.
[0116] 177 For Lu-labeled compounds, uptake in BxPc-3 tumors is always [ 177 Compared to LuDOTA-5G 177 Lu]LuDOTA-ABM-5G was at least four times larger. 177 When Lu]LuDOTA-5G was injected, tumor uptake was 1.23±0.19%ID / g at 1 hour and 0.81±0.16%ID / g at 72 hours (p=0.043), showing a slight washout over time. In contrast, [ 177 Tumor uptake of Lu]LuDOTA-ABM-5G was 4.54±0.42% ID / g at 1 hour and was retained for up to 72 hours (5.29±0.75% ID / g) (Figure 4A).
[0117] Both tracers showed uptake into the kidney and were washed out over time. 177 For Lu]LuDOTA-5G, the acquisition rate was 12.23±3.91%ID / g at 1 hour and 6.16±1.45%ID / g at 72 hours (p=0.0653). 177In Lu]LuDOTA-ABM-5G as well, uptake was 20.89±3.1% ID / g at 1 hour and 8.84±1.15% ID / g at 72 hours (p=0.0032), showing a washout of activity over time (Figure 4B). The resulting BxPC-3 / kidney uptake was [ 177 For LuDOTA-5G, the values are 0.08±0.05 (1 hour) and 0.14±0.05 (72 hours), [ 177 For Lu]LuDOTA-ABM-5G, the values were 0.22±0.05 (1 hour) and 0.60±0.02 (72 hours) (Figure 4C).
[0118] [ 68 As was evident in the case of Ga]GaDOTA-ABM-5G, ABM causes [ 177 An increase in the circulation of Lu]LuDOTA-ABM-5G was observed. 177 Lu]LuDOTA-ABM-5G's %ID / g is, 177 Compared to 0.10±0.02 for Lu]LuDOTA-5G, the result was 5.36±0.71%ID / g after 1 hour. 177 Lu]LuDOTA-5G became undetectable in the blood at a later date, 177 Lu]LuDOTA-ABM-5G remained measurable even after 72 hours (0.01±0.00%ID / g) (Tables 2 and 3).
[0119] (Table 2) BxPC-3(α v In mice with β6(+) tumors [ 177 In vivo distribution of Lu]LuDOTA-5G (n=3 / group / time period). TIFF2023552383000013.tif107165
[0120] (Table 3) BxPC-3(α v In mice with β6(+) tumors [ 177 In vivo distribution of Lu]LuDOTA-ABM-5G (n=3 / group / time period). TIFF2023552383000014.tif102165
[0121] [ 68 Ga]GaDOTA-5G and [ 68 As seen in the case of Ga]GaDOTA-ABM-5G, increased [ 177 Lu]LuDOTA-5G and [ 177 Uptake of both Lu]LuDOTA-ABM-5G was observed in the stomach, and radioactivity disappeared over time;[ 177 Lu]LuDOTA-5G's %ID / g -4.10±0.98 (1 hour) and 0.95±0.13 (72 hours) (p=0.0053), [ 177 Lu]LuDOTA-ABM-5G-9.16±0.58 (1 hour) and 4.76±1.22 (72 hours) (p=0.0049). The obtained BxPC-3 / stomach ratio was, [ 177 For LuDOTA-5G, the values were 0.31±0.06 (1 hour) and 0.87±0.28 (72 hours), [ 177 For Lu]LuDOTA-ABM-5G, the uptake was 0.50±0.08 (1 hour) and 1.16±0.30 (72 hours) (Figure 4D). In the large intestine, a similar uptake trend was observed, 177 Lu]LuDOTA-5G and [ 177 Observed in both Lu]LuDOTA-ABM-5G and at 4 hours [ 177 Lu]LuDOTA-5G has <4% ID / g, 177 In Lu]LuDOTA-ABM-5G, the value was <7%ID / g, and both decreased significantly over time (from 4 hours to 72 hours, p=0.0006, 177 Lu]LuDOTA-5G;p=0.0241, 177 Lu]LuDOTA-ABM-5G). The BxPC-3 / colon ratio is [ 177 Lu]LuDOTA-5G showed 0.31±0.02 (1 hour) and 1.74±0.39 (72 hours), [ 177 With Lu]LuDOTA-ABM-5G, the uptake was 0.77±0.25 (1 hour) and 1.77±0.26 (72 hours). Liver uptake was [ 177 Lu]LuDOTA-5G is <0.2%ID / g, 177For Lu]LuDOTA-ABM-5G, the value was <1%ID / g, and both decreased significantly over time.
[0122] [ 68 Ga]GaDOTA-5G, 177 Lu]LuDOTA-5G, and [ 177 Pre-administration of the respective blocking peptide (DOTA-5G or DOTA-ABM-5G) 10 minutes before administration of Lu]LuDOTA-ABM-5G resulted in reduced uptake in BxPC-3 tumors. Uptake was observed 1 hour after injection, [ 68 In GaDOTA-5G, the ID / g decreased from 2.6±0.79% to 0.27±0.02% (Δ=-86%), 177 In LuDOTA-5G, the ID level decreased from 1.23±0.19% to 0.3±0.02% (Δ=-75%). 177 For Lu]LuDOTA-ABM-5G, tumor uptake decreased from 7.15±3.04%ID / g to 4.12%ID / g 4 hours after injection (Δ=-42%) (Figures 5-7).
[0123] Example 7: In vivo targeted radionuclide therapy For in vivo targeted radionuclide therapy, BxPc-3 tumor cells were transplanted subcutaneously into mice 14 days prior to the start of treatment. Mice were randomly selected and divided into four treatment groups: control saline (group 1, n=5); control peptide DOTA-ABM-5G (group 2, n=6); 1 × 74 MBq[ 177 Lu]LuDOTA-ABM-5G (group 3, n=10); and 2×37MBq[ 177 Lu]LuDOTA-ABM-5G (Group 4, n=7). Mean tumor volume at the start of treatment was 14-218 mm². 3Group 2 received 20 μg of the peptide DOTA-ABM-5G per mouse as a control. Group 3 received 74 MBq on day 14 post-tumor transplantation (day 0 of treatment), and Group 4 received two doses of 37 MBq on days 14 and 21 post-tumor transplantation (days 0 and 7 of treatment), with a specific activity of 18.5 MBq / nmol. Body weight and tumor volume were measured the day before treatment and twice weekly after treatment throughout the study. Tumor volume (TV) was determined according to the equation TV=(π / 6)*L*W*H, where L is the longest axis, W is the axis perpendicular to L, and H is perpendicular to the plane of L and W. Endpoint determination was based on deterioration of the mouse's health, including TV longest axis exceeding 2 cm, radiation ulceration, or weight loss exceeding 20% from the start of the study. Survival curves were presented as Kaplan-Meier plots with the start of treatment as day 0.
[0124] All mice in control groups 1 (saline control) and 2 (peptide control) met the endpoint criteria (2 cm or more in any direction and / or tumor ulceration) by 63 and 68 days, respectively, from the start of treatment. In contrast, mice in group 3 (74 MBq) and group 4 (2 x 37 MBq) showed survival rates of 30% and 43%, respectively, at the end of the study (120 days). The median survival time of mice after treatment in each group was 56 days (groups 1 and 2), 82 days (group 3), and 113 days (group 4) (Figure 8B). No adverse events or weight loss were observed in any group during the study period (Figures 9A and 9B). Furthermore, no adverse effects were observed in blood chemistry tests.
[0125] Example 8: Single-center pilot study A pilot study was conducted at a single institution. All minority groups and both sexes were included.
[0126] Overview of research design / intervention The patient first, 177 To evaluate eligibility for Lu]LuDOTA-ABM-5G therapy, 68Patients received a single microdose of Ga]GaDOTA-5G PET / CT. Only patients with sufficient lesion uptake (visualized lesions with SUVmax more than twice that of normal lung or liver) received [ 177 Treatment with Lu]LuDOTA-ABM-5G was provided. This study was conducted by [ 177 This study was designed as a 3+3 dose escalation study using Lu]LuDOTA-ABM-5G. The treatment plan was: 177 The study consisted of a single dose of Lu]LuDOTA-ABM-5G. The 3+3 design included three patients in the first radioactivity level group (25 mCi) (see Table 4 below). Dose-limiting toxicity (DLT) was defined as a treatment-related adverse event of grade 3 (G3) or higher. Furthermore, the radiation dose to the kidneys should not exceed 23 Gy, and the radiation dose to the bone marrow should not exceed 1.5 Gy. If no DLT occurred within 30 days (after the third patient), the three patients were enrolled at the next dose level. If a patient was unable to participate in a full assessment of treatment-related toxicity within the 30-day DLT period due to a non-treatment-related issue, that patient was replaced for the purpose of DLT assessment at the same dose level. If DLT attributable to the study treatment was experienced in exactly 1 / 3 of the subjects in the first course, three more patients (total of 6) were treated at that dose level. If no additional DLT was observed at the extended dose level (i.e., 1 / 6 of those with DLT), the dose was increased. The dose escalation stopped as soon as two or more subjects experienced a DLT (drug-limiting thrombosis) caused by the investigational drug. In Phase II, it is recommended that the maximum dose (200 mCi limit) be maintained at one DLT or less per six patients. Furthermore, the radiation dose to the kidney should not exceed 23 Gy, and the radiation dose to the bone marrow should not exceed 1.5 Gy. Table 4 shows the dose escalation in the study.
[0127] (Table 4) 177 Gradual dose increase of Lu]LuDOTA-ABM-5G. TIFF2023552383000015.tif52165
[0128] Patients who met the registration criteria were registered by their attending oncologist or surgeon. All new patients were asked to complete a standard consent form for disclosure of health information, and where applicable, researchers were allowed to request past clinical laboratory and medical history information for the five years prior to the procedure from the referring physician or primary care physician.
[0129] Inclusion Criteria [ 68 Ga]GaDOTA-5GPET / CT Inclusion Criteria: 1. You must understand and be willing to sign a written informed consent document. 2. Must be 18 years of age or older. 3. Confirmation of locally advanced, unresectable, or metastatic pancreatic adenocarcinoma (excluding other pancreatic malignant histological types) with measurable disease according to RECIST (version 1.1) (i.e., at least one lesion greater than 1 cm or a lymph node greater than 1.5 cm in its short axis). 4. Participants must have a record of at least one previous systemic therapy-related tumor progression, established by a CT or MRI scan within 28 days of enrollment. 5. The performance status by the Eastern United States Oncology Collaborative Research Group is 2 or lower. 6. Participants, 68 Chemotherapy must be completed at least two weeks (washout period) before the Ga]GaDOTA-5G PET scan. Clinically significant toxicity (excluding alopecia and sensory neuropathy) related to prior treatment must be resolved to Grade 1 or baseline. 7. Hematological parameters are defined as follows: a. Absolute neutrophil count (ANC) is 1000 cells / mm³ 3 That's all. b. Platelet count is 100,000 / mm³ 3 That's all. c. Hemoglobin ≥ 8 g / dL. 8. Blood chemistry levels are defined as follows: a. AST, ALT, and alkaline phosphatase levels are less than 5 times the upper limit of normal (ULN). b. Total bilirubin less than twice the ULN (ultraluminal bone density) c. Creatinine level less than twice the ULN level. 9. Expected life expectancy is 3 months or more. 10. It can remain stationary for up to 30-60 minutes between scans.
[0130] [ 177 Inclusion criteria for Lu]LuDOTA-ABM-5G therapy: 1.[ 68 Entry to the Ga]GaDOTA-5GPET study and scanning completed. 2.[ 68 Presence of at least one measurable disease by Ga]GaDOTA-5G PET / CT (SUVmax greater than twice that of normal lung or liver).
[0131] Exclusion criteria [ 68 Ga]GaDOTA-5G and [ 177 Exclusion criteria for Lu]LuDOTA-ABM-5G therapy: 1. Participants in warfarin anticoagulation therapy 2. Participants with NYHA congestive heart failure in class 3 or 4 3. Clinically significant bleeding within two weeks prior to participation in the clinical trial (e.g., gastrointestinal bleeding, intracranial hemorrhage) 4. Pregnant or breastfeeding women 5. Major surgery: Defined as a surgical procedure scheduled within 28 days prior to day 1 of the study or within 6 weeks thereafter, involving general anesthesia and a significant incision (i.e., larger than the incision required for central venous access, percutaneous feeding tube placement, or biopsy placement). 6. You have an additional active malignant tumor that requires treatment within the past two years. 7. Uncontrolled active bacterial, viral, or fungal infections despite systemic therapy. 8. Mental illness / social circumstances that hinder compliance with research requirements 9. History of external beam radiation therapy to more than 25% of the bone marrow. 10. I cannot undergo a PET / CT or SPECT / CT scan due to my weight limit (350 pounds). 11. INR is greater than 2.0; PTT is more than 15 seconds faster than UNL.
[0132] Target treatment Pre-treatment evaluation Prior to initiating treatment, the patient underwent an outpatient consultation including a medical history review, physical examination, vital signs assessment, electrocardiogram, and ECOG evaluation. Furthermore, standard treatment laboratory tests were performed. These included liver function (ALT, AST, ALP, albumin, bilirubin), renal function (creatinine and creatinine clearance), and CBC (Hb, white blood cell count, platelet count). Blood alpha v Blood samples for exploratory results to assess β6 levels were collected at baseline (exploratory). Patient demographics include sex, age, time since diagnosis, and previous treatments.
[0133] research intervention [ 68 Ga]GaDOTA-5GPET / CT study. The patient, 68 Ga]GaDOTA-5G PET / CT scan, [ 177 Eligibility for Lu]LuDOTA-ABM-5G therapy has been confirmed. 68 Prior to the Ga]GaDOTA-5GPET / CT, patients were encouraged to drink enough water to urinate every hour on the day of the infusion. No special fasting was required. Maximum 185 MBq (5 mCi) [ 68 Ga]GaDOTA-5G (formula II below) was administered intravenously as a bolus. Vital signs (heart rate, pulse oximetry, body temperature, electrocardiogram) were measured immediately after injection. Patients were encouraged to urinate if possible. Patients [ 68 Approximately one hour after injection of Ga]GaDOTA-5G, a scan was performed from the apex of the skull to the proximal femur. For the calculation of the time-activity curve, 1 mL blood samples were taken at a series of time points throughout the uptake period (approximately 5, 10, 15, 30, and 60 minutes after injection). Vitals, blood samples, and electrocardiograms were also recorded. 68 Patients were checked 1 and 7 days (±48 hours) after injection of Ga]GaDOTA-5G, and clinical tests for complete chemistry, hematology, and liver function were performed. TIFF2023552383000016.tif51128 68 Ga = Gallium-68 DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid 5G = PEG 28 -GNGVPNLRGDLQVLGQRVGRT-PEG 28 -C(O)NH2 peptide
[0134] [ 177 [Lu]LuDOTA-ABM-5G therapy study. [ 68 Patients deemed eligible based on Ga]GaDOTA-5G PET / CT are, 68 Ga] GaDOTA-5G scan within 4 weeks (±7 days) 177 [Lu]LuDOTA-ABM-5G therapy was scheduled to be administered as a single dose. 177 Prior to administration of Lu]LuDOTA-ABM-5G, patients were encouraged to drink enough water to urinate every hour on the day of infusion and the following day. 177 After Lu]LuDOTA-ABM-5G treatment, patients were encouraged to have a bowel movement daily for up to one week and to use laxatives as needed. The physician explained to the patient general recommendations and precautions to follow to limit radiation exposure to third parties. For renal protection purposes, a 4-hour simultaneous infusion of an amino acid solution containing L-lysine [18g-24g] and L-arginine [18g-24g] was recommended. 177 The infusion of Lu]LuDOTA-ABM-5G was started 30 minutes prior to the infusion and continued at a constant rate (250cc / hr) for a total of 4 hours. The patient was monitored for 1 hour after the completion of the amino acid solution infusion. 177The administration of amino acid solutions before, during, and after Lu]LuDOTA-ABM-5G therapy is based on the experience of Lu-177DOTATATE to flush out radionuclides through the proximal tubules and reduce the radiation dose to the kidneys. To avoid treatment-related nausea and vomiting, antiemetics, including anti-H3 analogs (e.g., ondansetron), were started 30 minutes before the start of amino acid infusion, following hospital procedures. During amino acid administration and for several hours thereafter, patients were encouraged to urinate as frequently as possible.
[0135] [ 177 In vivo distribution and dose measurements were evaluated using nuclear imaging on days 1 and 7 after injection of Lu]LuDOTA-ABM-5G. Patients were [ 177 Approximately 24 and 168 hours after administration of Lu]LuDOTA-ABM-5G, whole-body planar imaging (anterior and posterior views) and SPECT / CT (cranial apex passing through the perineum and ending at the proximal femur, approximately 2-4 bed positions) were performed. Furthermore, in order to evaluate the in vivo distribution, [ 177 Sequential blood samples were collected approximately 5, 15, 30, 60, 120, and 180 minutes after administration of Lu]LuDOTA-ABM-5G. Complete chemistry, hematology, liver function tests, and electrocardiograms were performed on day 1 and day 7 (±48 hours).
[0136] Safety evaluation, 177 Clinical laboratory tests were performed approximately every two weeks for up to 90 days after Lu]LuDOTA-ABM-5G infusion to assess the potential for delayed toxicity. These included liver function (ALT, AST, ALP, albumin, bilirubin), renal function (creatinine and creatinine clearance), and hematology (Hb, white blood cell count, platelet count). Patients were followed up until death or loss of follow-up to assess the potential for late adverse events due to radiotherapy.
[0137] The effectiveness of exploratory studies is determined by correlation with CT or MRI imaging of standard treatment for disease monitoring. 177 It was expected to be obtained within 3 months after injection of Lu]LuDOTA-ABM-5G.
[0138] In this study, no significant risks to patients were anticipated, but safety in this study was assessed through monitoring of all serious and non-serious adverse events (AEs) as defined and graded according to NCICTCAEV5.0. All patients were followed for 90 days for AEs. Patients with ongoing study treatment-related AEs at study completion or termination were followed until the event resolved to Grade 1 or baseline grade (excluding alopecia and sensory neuropathy), until the event was determined to be stable by the investigator, until new anticancer drug therapy was initiated, until the patient could no longer be followed, until the patient withdrew consent, or until it was determined that participation in the investigational treatment or study was not the cause of the AE.
[0139] Analysis of interventions [ 68 The ability of Ga]GaDOTA-5G to detect translocations is demonstrated in at least one translocation. 68 [Ga]GaDOTA-5G uptake was assessed by increased uptake (SUVmax more than twice that of normal lungs or liver), 68 Ga]GaDOTA-5GPET / CT data are summarized as frequency, proportion, and accurate 95% confidence interval for the proportion.
[0140] Safety Analysis: Given that this is the first human study, the primary objectives are to define safety and tolerability and characterize the AE profile. Safety, tolerability, and AEs are summarized using descriptive statistics. 68 Ga]GaDOTA-5G and [ 177 AEs observed in Lu]LuDOTA-ABM-5G are summarized as frequency, patient proportion, and exact 95% confidence interval of the proportion, and classified by cohort, type, and severity. Adverse events (AEs) are graded using the Common Terminology Criteria for Adverse Events Version 5 (CTCAE). Dose-limiting toxicity is defined as treatment-related AE of grade 3 (G3) or higher. 68In the Ga]GaDOTA-5G study, paired t-tests were used to compare baseline and subsequent time to assess changes in specific vital signs on day 1 and day 7 (using appropriate transformations if necessary for normality). The population mean generalized estimation equation (GEE) was used to summarize the trajectory of changes in signs measured over multiple occasions. Diagnostic plots were used to identify potential outliers.
[0141] Efficacy analysis: All responses are reported using the RECIST 1.1 definition. Response rates and 95% accurate binomial confidence intervals are reported (exploratory).
[0142] Dosimetry analysis: (separate analysis for identifiable thoracic and abdominal organs, target lesions, and blood) 177 Descriptive statistics (mean, median, standard deviation, etc.) are reported for the AUC based on the radioactivity concentration-time curve of Lu]LuDOTA-ABM-5G, the maximum intake (achieved in %) in target lesions and identifiable organs, the specific absorbed dose for each organ (μGy / MBq), and the cumulative absorbed organ dose (Gy). Organs receiving the highest absorbed dose, as assessed by equivalent dose to tissue, are summarized in a table using frequency and percentage. Graphical tools are used to illustrate the endpoints.
[0143] Correlation analysis (exploratory): Analyze up to five lesions per patient that are clearly identifiable on SPECT / CT images from the dosemetry study. For each tumor lesion, the objective response to treatment is classified into a binary outcome (response vs. no response) according to the RECIST 1.1 criteria. The relationship between the response and the following dose measurements is evaluated: (i)[ 68 Ga]GaDOTA-5G data ingestion volume (SUV), (ii)[ 177 Lu]LuDOTA-ABM-5G ingestion volume (Gy), (iii)[ 177 Lu]LuDOTA-ABM-5G: Blood alpha before and after treatment v Differences in β6 levels, (iv) α in the blood after treatment vPredicted values for β6 levels. Attempts to model the relationship between response and radiation dose are primarily made using descriptive statistics, although logistic mixed-effects models may also be used where appropriate. Furthermore, the relationship between safety parameters (such as CBC and CMP) and the dose delivered to organs is evaluated using descriptive statistics and mixed-effects models. Appropriate transformations are applied to the results where necessary for normality (exploratory).
[0144] Radiation data Radiographic data captured as part of patient input (associated with each type of radiological examination, but from CT or MRI) includes: the location of the lesion within the pancreas, the maximum size of the lesion, the location and size of metastases.
[0145] PET / CT image data [ 68 The general distribution of Ga]GaDOTA-5G is determined by visual analysis of blood data and scans. Reconstructed PET / CT images (still images of the entire body from the apex of the skull to the proximal femur) are displayed on a GE imaging workstation and reoriented into maximum intensity projection (MIP), transaxial, coronal, and sagittal images. All PET, fused PET / CT, and CT images are examined. Regions of interest (ROIs) are placed around tracer-accumulating lesions suspected of malignancy and vital organs (e.g., kidneys, bladder, intestines, liver, spleen, lungs, pancreas) to obtain SUV parameters, including maximum and mean SUVs. All SUV measurements are summarized using mean, median, range, and count, and SUVs are correlated to tissue regions using a repeated measures ANOVA model. "Non-excreting" and "excreting" radioactivity are tracked. Non-excreted radioactivity in the body is calculated from volume of interest (VOI) analysis to derive the amount of radioactivity in major organs, tissues of interest, and the rest of the body. The data is adjusted to a "Reference Man" anthropomorphic model for dosimetry purposes. Organ activity is integrated over time to obtain time-integrated activity coefficients. Dose and effective dose measurements are obtained using OLINDA software.
[0146] SPECT / CT image data A full-body planar scan, 177 Used for qualitative evaluation of the Lu]LuDOTA-ABM-5G distribution. Kidney, stomach, liver (not involved), bone marrow, and whole body, and [ 177 The absorbed radiation dose to other organs showing accumulation of Lu]LuDOTA-ABM-5G is calculated based on the analysis of serial hematology and SPECT / CT scans. SPECT / CT study images are used to calculate volume absorbed radiation dose in diseased and healthy tissues. Specifically, radioactivity-time curves for normal tissue are generated from region of interest (ROI) analysis of SPECT / CT scans. Radioactivity-time curves for red bone marrow and cardiac contents are generated from blood radioactivity concentrations measured by a well scintillation counter. Volume of interest (VOI) is generated for each patient. Radioactivity concentrations in red bone marrow are assumed to be the same as those in blood. The radioactivity-time curves are integrated (e.g., analytically or numerically as needed) to obtain AUC values that generate so-called residence times. These data are used as input to the FDA-approved dosimetry software package OLINDA / EXM1.0 to generate absorbed dose estimates for normal tissue. The SPECT / CT acquisition and reconstruction study protocol follows the Lu-tetium-177 SPECT-based dosimetry guidelines established by MIRD26. SPECT / CT scanner calibration is performed using a homogeneous water phantom containing a calibrated Lu-177 source (e.g., 1 mCi). Supplemental dosimetry assessment includes lesion absorbed dose estimates based on image ROI analysis. Absorbed doses are normalized to the administered radioactivity and expressed in mGy / MBq.
[0147] Blood data (exploratory) Serum was collected from patients, and the samples were stored at -80°C to avoid loss of biological activity. vβ6 concentrations were quantitatively measured using a human ITGB6 enzyme-linked immunosorbent assay (ELISA) detection kit purchased from Cloud-CloneCorp (SEC099Hu, Texas, USA) according to the manufacturer's instructions. The concentration was calculated in ng / mL, and this data was associated with image data and treatment data.
[0148] Dose levels and initial patient assessment Patients at dose levels 1 and 2 were treated as described. Table 5 shows the patients' previous treatments and their status at registration. The radiation doses to the patients' kidneys and bone marrow are shown in Table 5 as organ-level internal dose assessment (OLINDA) and MRT. The initial status of the patients at the first two dose levels is shown in Table 6.
[0149] (Table 5) TIFF2023552383000017.tif157165
[0150] (Table 6) TIFF2023552383000018.tif72165
[0151] VII. Exemplary Embodiments Exemplary embodiments provided in accordance with the subject matter of this disclosure include, but are not limited to, the claims and the following embodiments.
[0152] 1.α v A method for treating β6 integrin-related cancer, comprising administering a certain dose of a therapeutic conjugate of formula I to a subject in need of treatment, In the TIFF2023552383000019.tif61128 formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. And, The therapeutic conjugate in the aforementioned dose contains radioactivity of approximately 25 mCi to approximately 200 mCi. The aforementioned method.
[0153] 2. The method according to Embodiment 1, wherein the first PEG portion and the second PEG portion each contain PEG28 (PEG1500).
[0154] 3. The method according to Embodiment 1 or 2, wherein the amount of radioactivity in the dose is 25 mCi, 50 mCi, 100 mCi, 150 mCi, or 200 mCi.
[0155] 4. The method according to any one of Embodiments 1 to 3, further comprising administering 1, 2, or 3 additional doses of the therapeutic conjugate to the subject.
[0156] 5. The method according to any one of Embodiments 1 to 4, comprising the peptide in a dose of approximately 100 μg or less.
[0157] 6. The above α v The method according to any one of Embodiments 1 to 5, wherein the β6 integrin-related cancer is pancreatic cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, cutaneous squamous cell carcinoma, gastric cancer, or endometrial cancer.
[0158] 7. The method according to Embodiment 6, wherein the pancreatic cancer is locally advanced or metastatic pancreatic cancer; locally advanced, unresectable, or metastatic pancreatic adenocarcinoma; or pancreatic ductal adenocarcinoma (PDAC).
[0159] 8. The above α v The method according to any one of Embodiments 1 to 7, wherein the β6 integrin-related cancer includes both the primary tumor and metastatic tumors.
[0160] 9. The above α v The method according to any one of Embodiments 1 to 8, wherein the β6 integrin-related cancer includes lesions in the adrenal gland, bone, brain, liver, lung, or any combination thereof.
[0161] 10. The method according to any one of Embodiments 1 to 9, wherein the subject receives standard treatment before being administered the dose of the therapeutic conjugate.
[0162] 11. The method according to any one of Embodiments 1 to 10, wherein the subject receives standard treatment after being administered the therapeutic conjugate in the dose described above.
[0163] 12. The method according to Embodiment 10 or 11, wherein the standard treatment includes one or more of surgery, radiotherapy, chemotherapy, chemoradiotherapy, and targeted therapy.
[0164] 13. The method according to any one of Embodiments 10 to 12, wherein the standard treatment comprises FOLFIRINOX (leucovorin calcium (folic acid), fluorouracil, irinotecan hydrochloride, and oxaliplatin), gemcitabine, Abraxane, irinotecan, or a combination thereof.
[0165] 14. The method according to any one of Embodiments 1 to 13, further comprising scanning the body or part thereof of the subject after administering the therapeutic conjugate.
[0166] 15. The method according to Embodiment 14, wherein the scanning includes positron emission tomography (PET), computed tomography (CT) scanning, or single-photon emission computed tomography (SPECT).
[0167] 16. The method according to any one of Embodiments 1 to 15, further comprising administering a diagnostic conjugate before administering the therapeutic conjugate, wherein the diagnostic conjugate comprises an RGD peptide and a second radionuclide.
[0168] 17. The second radionuclide is 68 The method according to embodiment 16, wherein the material is Ga.
[0169] 18. The method according to Embodiment 16 or 17, wherein the diagnostic conjugate is administered in a dose containing a maximum of approximately 5 mCi of radioactivity.
[0170] 19. The method according to any one of embodiments 16 to 18, further comprising scanning the body or part thereof of the subject after administering the diagnostic conjugate.
[0171] 20. The method according to Embodiment 19, wherein the scanning includes positron emission tomography (PET), computed tomography (CT) scanning, or single-photon emission computed tomography (SPECT).
[0172] 21. The method according to any one of Embodiments 16 to 20, wherein the therapeutic conjugate is administered within 5 weeks after the administration of the diagnostic conjugate.
[0173] 22. The diagnostic conjugate includes formula II, In the TIFF2023552383000020.tif51128 formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. The method according to any one of embodiments 16 to 21.
[0174] 23. The method according to Embodiment 22, wherein the first PEG portion and the second PEG portion each contain PEG28 (PEG1500).
[0175] 24. The method according to any one of Embodiments 1 to 23, further comprising administering an amino acid solution to the subject.
[0176] 25. The method according to Embodiment 24, wherein the solution is administered before and simultaneously with the administration of the therapeutic conjugate.
[0177] 26. The method according to any one of Embodiments 1 to 25, wherein the therapeutic conjugate is administered to the subject by injection.
[0178] 27. The method according to any one of embodiments 16 to 26, wherein the diagnostic conjugate is administered to the subject by injection.
[0179] 28. The method according to any one of Embodiments 1 to 27, wherein the treatment results in stable disease, partial remission, or complete remission.
[0180] 29. The method according to any one of Embodiments 1 to 28, wherein the treatment results in a reduction of the metastasis of the cancer in the subject.
[0181] 30. The method according to any one of Embodiments 1 to 29, wherein the treatment results in a reduction in the volume, size, or growth of the tumor in the subject.
[0182] 31. The method according to any one of Embodiments 1 to 30, wherein the treatment increases the responsiveness of the cancer to an anticancer drug administered thereafter.
[0183] 32. The method according to any one of Embodiments 1 to 31, wherein the amount of the therapeutic conjugate present in the kidney tissue 24 hours, 48 hours, or 72 hours after administration of the conjugate is less than the amount of the therapeutic conjugate present in the kidney tissue 1 hour after administration of the conjugate.
[0184] 33. The method according to any one of Embodiments 1 to 32, wherein the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in the kidney tissue 24 hours, 48 hours, or 72 hours after administration of the conjugate is higher than the ratio of the amount of therapeutic conjugate in the primary tumor to the amount of therapeutic conjugate in the kidney tissue 1 hour after administration of the conjugate.
[0185] 34. A pharmaceutical composition comprising a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT.
[0186] 35. The pharmaceutical composition according to Embodiment 34, wherein the PEG portion is covalently bonded to the N-terminus, C-terminus, or both the N-terminus and the C-terminus of the peptide.
[0187] 36. The pharmaceutical composition according to Embodiment 35, wherein the PEG portion is independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2).
[0188] 37. The pharmaceutical composition according to Embodiment 35, wherein a first PEG portion is covalently bonded to the N-terminus of the peptide, a second PEG portion is covalently bonded to the C-terminus of the peptide, and the first PEG portion and the second PEG portion are independently selected from the group consisting of PEG11, PEG12 (PEG800), PEG28 (PEG1500), and (PEG28)2 (PEG1500 × 2).
[0189] 38. The pharmaceutical composition according to Embodiment 37, wherein the first PEG portion and the second PEG portion are the same.
[0190] 39. The pharmaceutical composition according to Embodiment 38, wherein the first PEG portion and the second PEG portion each contain PEG28 (PEG1500).
[0191] 40. The pharmaceutical composition according to any one of embodiments 34 to 39, wherein the peptide is covalently bonded to an albumin-binding site (ABM).
[0192] 41. The pharmaceutical composition according to Embodiment 40, wherein the ABM contains 4-(4-iodophenyl)butyric acid.
[0193] 42. The pharmaceutical composition according to Embodiment 40 or 41, wherein the ABM contains a K(D-Abu-iodophenylbutyryl) moiety.
[0194] 43. The pharmaceutical composition according to any one of embodiments 34 to 42, wherein the peptide is covalently bonded to the chelate portion.
[0195] 44. The pharmaceutical composition according to Embodiment 43, wherein the chelate portion is DOTA.
[0196] 45. The pharmaceutical composition according to Embodiment 43 or 44, wherein the radionuclide is complexed with the chelate moiety.
[0197] 46. The pharmaceutical composition according to any one of embodiments 34 to 45, wherein the radionuclide is directly or indirectly covalently bonded to the peptide.
[0198] 47. The radioactive nuclide is 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 PM, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, and 212 A pharmaceutical composition according to embodiment 46, selected from the group consisting of Bi.
[0199] 48. The radioactive nuclide is 11 C, 13 N, 15 O, 18 F, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 In, 124 I, 125 I, or 131 A pharmaceutical composition according to Embodiment 46, selected from the group consisting of I.
[0200] 49. Conjugate of Equation I: TIFF2023552383000021.tif61128(In the formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. (is), and Pharmacologically acceptable excipients A pharmaceutical composition containing the following:
[0201] 50. The pharmaceutical composition according to Embodiment 49, wherein the first PEG portion and the second PEG portion are the same.
[0202] 51. The pharmaceutical composition according to Embodiment 49 or 50, wherein the first PEG portion and the second PEG portion each contain PEG28 (PEG1500).
[0203] 52. The pharmaceutical composition according to any one of Embodiments 49 to 51, wherein the composition contains a radioactivity of about 25 mCi to about 200 mCi.
[0204] 53. Conjugate of Equation II: TIFF2023552383000022.tif51128(In the formula, 5G is, A PEGylated peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT, and containing a first PEG moiety at the N-terminus and a second PEG moiety at the C-terminus. (is), and Pharmacologically acceptable excipients A pharmaceutical composition containing the following:
[0205] 54. The pharmaceutical composition according to Embodiment 53, wherein the first PEG portion and the second PEG portion are the same.
[0206] 55. The pharmaceutical composition according to Embodiment 53 or 54, wherein the first PEG portion and the second PEG portion each contain PEG28 (PEG1500).
[0207] The examples and embodiments described herein are for illustrative purposes only, and various modifications or changes in light thereof will be suggested to those skilled in the art and will be understood to be within the spirit and scope of the claims of this application and the appended claims. All publications, patents, patent applications and sequence registration numbers cited herein are incorporated herein by reference in their entirety for all purposes.
Claims
1. A pharmaceutical composition comprising a peptide having the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (sequence number: 1).
2. The pharmaceutical composition of claim 1, wherein the peptide has an N-terminus and a C-terminus, and a PEG moiety is covalently bonded to the N-terminus, the C-terminus, or both the N-terminus and the C-terminus of the peptide.
3. The pharmaceutical composition of claim 1 or 2, wherein the peptide is covalently bound to an albumin binding moiety (ABM).
4. The pharmaceutical composition of claim 1, wherein the peptide is covalently bound to a chelating moiety.
5. The pharmaceutical composition of claim 4, wherein a radioactive nuclide is complexed with the chelating moiety.
6. The pharmaceutical composition of claim 5, wherein the radioactive nuclide is selected from the group consisting of alpha emitters, beta emitters, gamma emitters, and positron emitters.
7. The radionuclide is 32 P, 47 Sc, 67 Cu, 89 Sr, 90 Y, 105 Rh, 111 Ag, 117m Sn, 131 I, 149 Pm, 153 Sm, 166 Ho, 177 Lu, 186 Re, 188 Re, 211 At, 225 Ac, 212 Bi, 11 C, 13 N, 15 O, 18 F, 55 Co, 60 Cu, 61 Cu, 62 Cu, 64 Cu, 66 Ga, 67 Cu, 68 Ga, 82 Rb, 86 Y, 111 7. The pharmaceutical composition of claim 5 or 6, wherein the isotope is selected from the group consisting of In, 124I, 125I, and 131I.
8. The pharmaceutical composition of claim 5 or 6, wherein the radionuclide is 64 Cu or 67 Cu.
9. The pharmaceutical composition of claim 5 or 6, wherein the radionuclide is 68 Ga or 177 Lu.
10. The pharmaceutical composition of claim 1, further comprising a pharma- ceutically acceptable excipient, wherein the peptide has an N-terminus and a C-terminus, a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide to provide a PEGylated peptide, and further wherein the PEGylated peptide is provided as a conjugate of Formula I: wherein 5G is the PEGylated peptide.
11. The pharmaceutical composition of claim 1, further comprising a pharma- ceutically acceptable excipient, wherein the peptide has an N-terminus and a C-terminus, a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide to provide a PEGylated peptide, and further wherein the PEGylated peptide is provided as a conjugate of Formula II: wherein 5G is the PEGylated peptide.
12. The pharmaceutical composition described in claim 10 or 11, wherein the first PEG portion and the second PEG portion each comprise PEG28 (PEG1500).
13. A medicament for treating α v β 6 integrin associated cancer in a subject in need thereof comprising a dose of the pharmaceutical composition of any one of claims 1 to 10.
14. A medicament for treating an α v β 6 integrin-associated cancer in a subject in need thereof, comprising a dose of a pharmaceutical composition comprising a therapeutic conjugate of Formula I, wherein 5G is a PEGylated peptide having an N-terminus, a C-terminus, and the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO:1), and wherein a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide.
15. (a) The dose of the pharmaceutical composition comprises a radioactivity of about 25 mCi to about 200 mCi. (b) said dose of pharmaceutical composition comprises a radioactivity of about 25 mCi, about 50 mCi, about 100 mCi, about 150 mCi, or about 200 mCi; (c) the dose comprises 100 μg or less of the peptide; (d) the medicament further comprises one, two, or three additional doses of the pharmaceutical composition; and / or (e) The medicament comprises any combination of (a), (b), (c), and (d) above; The pharmaceutical composition according to claim 14.
16. The method of claim 13, wherein the α v β 6 integrin-associated cancer is selected from the group consisting of pancreatic cancer, breast cancer, colorectal cancer, lung cancer, ovarian cancer, cervical cancer, oral squamous cell carcinoma, cutaneous squamous cell carcinoma, head and neck cancer, gastric cancer, and endometrial cancer.
17. The pharmaceutical agent according to any one of claims 13 to 16, wherein the α v β 6 integrin-associated cancer comprises a metastatic lesion.
18. The pharmaceutical composition of any one of claims 13 to 17, wherein the subject receives standard treatment before and / or after administration of the pharmaceutical composition.
19. The pharmaceutical of claim 18, wherein the standard treatment includes one or more of surgery, radiation therapy, chemotherapy, chemoradiotherapy, and targeted therapy.
20. The pharmaceutical of claim 18 or 19, wherein the standard treatment includes one or more of leucovorin calcium (folinic acid), fluorouracil, oxaliplatin, gemcitabine, abraxane, and irinotecan.
21. A pharmaceutical described in any one of claims 13 to 20, wherein treatment with the pharmaceutical composition increases the responsiveness of the cancer to an anticancer agent administered after the pharmaceutical composition.
22. The pharmaceutical of any one of claims 13 to 21, further comprising a diagnostic conjugate comprising an RGD peptide and a second radionuclide, wherein the diagnostic conjugate is administered prior to administration of the pharmaceutical composition.
23. The pharmaceutical composition of claim 22, wherein the second radionuclide is selected from the group consisting of 11C, 13N, 15O, 18F, 55Co, 60Cu, 61Cu, 62Cu, 64Cu, 66Ga, 67Cu, 68Ga, 82Rb, 86Y, 111In, 124I, 125I, and 131I.
24. The diagnostic conjugate comprising formula II:
23. The pharmaceutical composition of claim 22, wherein 5G is a PEGylated peptide having an N-terminus, a C-terminus, and the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO: 1), and wherein a first PEG moiety is covalently attached to the N-terminus of the peptide and a second PEG moiety is covalently attached to the C-terminus of the peptide.
25. The method of claim 13, wherein the α v β 6 integrin-associated cancer is pancreatic cancer, locally advanced pancreatic cancer, metastatic pancreatic cancer, locally advanced, unresectable, or metastatic pancreatic adenocarcinoma, or pancreatic ductal adenocarcinoma.
26. The treatment, (a) stable disease, partial remission, or complete remission; (b) reducing metastasis of the cancer in the subject; and (c) reducing the volume, size, or growth of a tumor in said subject. The pharmaceutical agent according to any one of claims 13 to 25, which produces one or more of the following effects:
27. A composition for imaging a tumor, a cancerous lesion, or a cancer cell, comprising the pharmaceutical composition of any one of claims 1 to 9 and 11.
28. The composition of claim 27, further comprising a therapeutic agent.
29. The composition of claim 28, wherein the therapeutic agent comprises an RGD peptide.
30. A conjugate comprising a peptide and at least one moiety covalently bonded to the peptide, wherein the peptide comprises the amino acid sequence GNGVPNLRGDLQVLGQRVGRT (SEQ ID NO:1).
